

Financial news for MYGN dated on 2020-06-08: Myriad Genetics Highlights Study Of GeneSight Psychotropic Published In Psychiatry Research Journal

Financial news for MYGN dated on 2020-06-04: Myriad Genetics Highlights Publication Of Prospective Clinical Study Of EndoPredict Test In Women With Early-Stage Breast Cancer

Financial news for MYGN dated on 2020-05-29: Myriad Genetics Highlights New Data To Be Presented At ASCO On riskscore For Personalized Breast Cancer Risk Information to Patients

Financial news for MYGN dated on 2020-05-26: Cerecor And Myriad Genetics Announce 'Levels of LIGHT, a Novel Cytokine, Were Highly Correlated with Disease Severity and Mortality in COVID-19 ARDS Biomarker Study '

Financial news for MYGN dated on 2020-05-20: The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test

Financial news for MYGN dated on 2020-05-20: Myriad Genetics shares are trading higher after the company announced it has received FDA approval for BRACAnalysis CDx as a companion diagnostic for Lynparza for the treatment of adult patients with metastatic castration-resistant prostate cancer.

Financial news for MYGN dated on 2020-05-20: Myriad Receives FDA Approval Of BRACAnalysis CDx As A Companion Diagnostic For Lynparza In HRR-Mutated Metastatic Castration-Resistant Prostate Cancer

Financial news for MYGN dated on 2020-05-11: Myriad Genetics shares are trading higher after the company announced it has received FDA approval for the company's myChoice CDx-test as a companion diagnostic for Lynparza in patients with advanced ovarian cancer.

Financial news for MYGN dated on 2020-05-11: 15 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for MYGN dated on 2020-05-11: Myriad Receives FDA Approval Of myChoice CDx As Companion Diagnostic For Lynparza In Patients With Advanced Ovarian Cancer

Financial news for MYGN dated on 2020-05-06: JP Morgan Maintains Underweight on Myriad Genetics, Lowers Price Target to \$12

Financial news for MYGN dated on 2020-05-06: The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle

Financial news for MYGN dated on 2020-05-06: 33 Stocks Moving in Wednesday's Pre-Market Session

Financial news for MYGN dated on 2020-05-05: 10 Stocks Moving In Tuesday's After-Hours Session

Financial news for MYGN dated on 2020-05-05: Myriad Genetics shares are trading lower after the company reported worse-than-expected Q3 EPS and sales results.

Financial news for MYGN dated on 2020-05-05: Myriad Genetics Q3 EPS \$(0.080) Misses \$0.020 Estimate, Sales \$164.000M Miss \$167.190M Estimate

Financial news for MYGN dated on 2020-05-05: Myriad Genetics Option Alert: May 15 \$17 Calls at the Ask: 1000 @ \$1.7 vs 1052 OI; Earnings 5/5 After Close Ref=\$15.6

Financial news for MYGN dated on 2020-05-05: The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout

Financial news for MYGN dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for MYGN dated on 2020-04-20: Myriad Genetics Announces Publication of a Meta-Analysis Demonstrating the Clinical Utility of the GeneSight Psychotropic Test in People with Major Depressive Disorder

Financial news for MYGN dated on 2020-04-17: Shares of several healthcare companies are trading higher amid optimistic coronavirus outlook following positive drug data from Gilead. This has raised hopes of a sooner return to spending and economic activity.

Financial news for MYGN dated on 2020-04-08: The Daily Biotech Pulse: Genmark Pre-Announces Q1 Outperformance, Sage to Eliminate 53% of Workforce, Keros IPO

Financial news for MYGN dated on 2020-04-08: Myriad Withdrawing FY20 Guidance

Financial news for MYGN dated on 2020-04-07: 84 Biggest Movers From Yesterday

Financial news for MYGN dated on 2020-04-06: Shares of several healthcare companies are trading higher as markets gain amid optimism that coronavirus cases in several US hotspots may be peaking. A sooner peak could mean a sooner return to economic activity.

Financial news for MYGN dated on 2020-04-06: Myriad Receives Reimbursement For BRACAnalysis Diagnostic System In Japan For Patients With Breast Or Ovarian Cancer Associated With HBOC

Financial news for MYGN dated on 2020-04-02: B of A Securities Reiterates Underperform on Myriad Genetics, Lowers Price Target to \$13

Financial news for MYGN dated on 2020-03-30: Myriad Seeks Japanese Regulatory Approval for its BRACAnalysis Diagnostic System in People with Advanced Pancreatic and Prostate Cancer

Financial news for MYGN dated on 2020-03-27: Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus package boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.

Financial news for MYGN dated on 2020-03-26: Barclays Maintains Underweight on Myriad Genetics, Lowers Price Target to \$10

Financial news for MYGN dated on 2020-03-19: The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latest Stage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection

Financial news for MYGN dated on 2020-03-18: The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates

Financial news for MYGN dated on 2020-03-18: Myriad's Says NCCN Updated Professional Guidelines Recommending Biomarker Testing For Unfavorable Intermediate And High-Risk Prostate Cancer Patients; Notes Co.'s Prolaris Test Was 'one of only two prognostic tests for prostate cancer' Recommended

Financial news for MYGN dated on 2020-03-17: The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment

Financial news for MYGN dated on 2020-03-13: The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings

Financial news for MYGN dated on 2020-03-12: Stocks That Hit 52-Week Lows On Thursday

Financial news for MYGN dated on 2020-03-12: The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO

Financial news for MYGN dated on 2020-03-11: The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment

Financial news for MYGN dated on 2020-03-10: Stocks That Hit 52-Week Lows On Tuesday

Financial news for MYGN dated on 2020-03-10: The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos To Join S&P SmallCap 600 Index

Financial news for MYGN dated on 2020-03-06: Stocks That Hit 52-Week Lows On Friday

Financial news for MYGN dated on 2020-02-28: Stocks That Hit 52-Week Lows On Friday

Financial news for MYGN dated on 2020-02-28: The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO

Financial news for MYGN dated on 2020-02-27: Stocks That Hit 52-Week Lows On Thursday

Financial news for MYGN dated on 2020-02-27: The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lilly, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy

Financial news for MYGN dated on 2020-02-26: The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates

Financial news for MYGN dated on 2020-02-25: The Daily Biotech Pulse: Moderna Ships

COVID-19 Vaccine For Clinics, Mallinckrodt Strikes \$1.6B Opioid Settlement

Financial news for MYGN dated on 2020-02-18: Myriad Genetics Shares Spike To Session High As Hearing Co. Wins Aetna Insurance Coverage For Its BRACAnalysis CDx Diagnostic

Financial news for MYGN dated on 2020-02-14: Myriad Genetics Highlights Presentation Of New Data On Ability Of Prolaris To Predict Men With Prostate Cancer At American Society of Clinical Oncology Genitourinary Cancer Symposium

Financial news for MYGN dated on 2020-02-11: Myriad Submits sPMA For myChoice CDx With Lynparza In First-Line Maintenance Therapy In Advanced Ovarian Cancer

Financial news for MYGN dated on 2020-02-10: 30 Stocks Moving in Monday's Pre-Market Session

Financial news for MYGN dated on 2020-02-10: 95 Biggest Movers From Friday

Financial news for MYGN dated on 2020-02-07: Mid-Afternoon Market Update: Dow Falls Over 300 Points; Assertio Therapeutics Shares Spike Higher

Financial news for MYGN dated on 2020-02-07: Mid-Morning Market Update: Markets Open Lower; US Adds 225,000 Jobs For January

Financial news for MYGN dated on 2020-02-07: 2 Diagnostics & Research Stocks Moving In Friday's Pre-Market Session

Financial news for MYGN dated on 2020-02-07: 16 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for MYGN dated on 2020-02-07: The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns

Financial news for MYGN dated on 2020-02-07: 46 Stocks Moving in Friday's Pre-Market Session

Financial news for MYGN dated on 2020-02-07: Myriad Genetics shares are trading lower after the company reported worse-than-expected Q2 EPS and sales results. The company also reported the President and CEO, Mark Capone, resigned.

Financial news for MYGN dated on 2020-02-06: 29 Stocks Moving In Thursday's After-Hours Session

Financial news for MYGN dated on 2020-02-06: Myriad Genetics shares are trading lower after the company reported worse-than-expected Q2 EPS and sales results. The company also reported the President and CEO, Mark Capone, resigned.

Financial news for MYGN dated on 2020-02-06: Myriad Genetics Reports Pres, CEO Mark Capone Resigned; CFO R. Bryan Riggsbee Named Interim Replacement

Financial news for MYGN dated on 2020-02-06: Myriad Genetics Sees Q3 Adj. EPS \$0.02 vs \$0.30 Estimate, Sales \$172M vs \$201M Est.; FY20 Adj. EPS \$0.45 vs \$1.06 Est., Sales \$735M vs \$807M Est.

Financial news for MYGN dated on 2020-02-06: Myriad Genetics Q2 Adj. EPS \$0.23 Misses \$0.31 Estimate, Sales \$195.1M Miss \$209.81M Estimate

Financial news for MYGN dated on 2020-02-06: The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs

Financial news for MYGN dated on 2020-02-06: Earnings Scheduled For February 6, 2020

Financial news for MYGN dated on 2020-02-02: The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus

Financial news for MYGN dated on 2020-01-28: Gene-editing/sequencing stocks trading higher following finalization of national coverage decision by Centers for Medicare & Medicaid Services related to next-gen sequencing.

Financial news for MYGN dated on 2020-01-23: Myriad Genetics Submits sPMA for myChoice CDx with Zejula in First-Line Platinum Responsive Advanced Ovarian Cancer

Financial news for MYGN dated on 2020-01-21: Myriad Submits sPMA For BRACAnalysis CDx As A Companion Diagnostic For Lynparza In Metastatic Castration-resistant Prostate Cancer

Financial news for MYGN dated on 2020-01-13: Enzo Biochem Responds to Statements From Activist Hedge Fund Harbert

Financial news for MYGN dated on 2020-01-03: Benzinga's Top Upgrades, Downgrades For

January 3, 2020

Financial news for MYGN dated on 2019-12-30: 38 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for MYGN dated on 2019-12-30: 25 Stocks Moving in Monday's Pre-Market Session

Financial news for MYGN dated on 2019-12-30: Myriad Receives FDA Approval Of BRACAnalysis CDx As Companion Diagnostic For Lynparza In Patients With Germline BRCA-mutated Metastatic Pancreatic Cancer

Financial news for MYGN dated on 2019-12-26: 51 Biggest Movers From Tuesday

Financial news for MYGN dated on 2019-12-24: 33 Stocks Moving In Tuesday's Mid-Day Session

Financial news for MYGN dated on 2019-12-24: Myriad Genetics shares are trading higher on a potential rebound following the ~10% dip yesterday.

Financial news for MYGN dated on 2019-12-24: 78 Biggest Movers From Yesterday

Financial news for MYGN dated on 2019-12-23: 44 Stocks Moving In Monday's Mid-Day Session

Financial news for MYGN dated on 2019-12-23: Myriad Genetics shares are trading lower. Not currently seeing any company-specific news. Traders circulate bearish Motley Fool article comparing the stock to peer Exact Sciences, which it says expects to 'deliver significantly more growth in the future.'

Financial news for MYGN dated on 2019-12-23: Myriad Genetics Option Alert: May 15 \$23 Puts Sweep (33) near the Bid: 557 @ \$2.351 vs 11 OI; Earnings 2/4 After Close [est] Ref=\$24.8099

Financial news for MYGN dated on 2019-12-04: Myriad Genetics Highlights Publication Of New Study Of Its Prequel Prenatal Screen In Prenatal Diagnosis Journal

Financial news for MYGN dated on 2019-12-02: Shares of several healthcare stocks are trading lower as US equities dip following escalating US-China tensions over Hong Kong. US Stocks further fell on worse-than-expected manufacturing data.

Financial news for MYGN dated on 2019-11-21: Myriad Genetics Reports Japan's Ministry Of Health, Labour, Welfare Approved BRACAnalysis System

Financial news for MYGN dated on 2019-11-11: Myriad Announces Prequel Prenatal Screen Demonstrates High Performance Across All Fetal-Fraction Levels in Women Undergoing Noninvasive Prenatal Screening -

Financial news for MYGN dated on 2019-11-06: Myriad Genetics shares are trading higher after the company announced data from the GUIDED clinical trial showed GeneSight Psychotropic test improved clinical outcomes for people with depression who were taking medications with gene-drug interactions.

Financial news for MYGN dated on 2019-11-06: The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings

Financial news for MYGN dated on 2019-11-06: Myriad Genetics Highlights Results From New Analysis Of GUIDED Clinical Trial Published In Journal Of Clinical Psychiatry Showing Its GeneSight Psychotropic Test Improved Clinical Outcomes In Patients Taking Medications With Gene-Drug Interactions

Financial news for MYGN dated on 2019-11-06: 61 Biggest Movers From Yesterday

Financial news for MYGN dated on 2019-11-05: Mid-Afternoon Market Update: Dow Gains 80 Points; Fulgent Genetics Shares Jump Following Strong Q3 Results

Financial news for MYGN dated on 2019-11-05: Mid-Day Market Update: EverQuote Rises After Upbeat Q3 Results; Armstrong Flooring Shares Plummet

Financial news for MYGN dated on 2019-11-05: 54 Stocks Moving In Tuesday's Mid-Day Session

Financial news for MYGN dated on 2019-11-05: Stocks That Hit 52-Week Lows On Tuesday

Financial news for MYGN dated on 2019-11-05: Mid-Morning Market Update: Markets Mixed; Emerson Electric Profit Beats Views

Financial news for MYGN dated on 2019-11-05: Myriad Genetics shares are trading lower after the company reported Q1 EPS of \$0.08 compared to the \$0.32 estimate and worse-

than-expected Q1 sales results. The company also issued Q2 and FY20 EPS and sales guidance below analyst estimates.

Financial news for MYGN dated on 2019-11-05: 10 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for MYGN dated on 2019-11-05: 24 Stocks Moving in Tuesday's Pre-Market Session

Financial news for MYGN dated on 2019-11-05: The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment

Financial news for MYGN dated on 2019-11-04: Myriad Genetics shares are trading lower after the company reported Q1 EPS of \$0.08 compared to the \$0.32 estimate and worse-than-expected Q1 sales results. The company also issued Q2 and FY20 EPS and sales results below analyst estimates.

Financial news for MYGN dated on 2019-11-04: Myriad Genetics Sees FY20 Adj. EPS \$1-\$1.10 vs \$1.82 Estimate, Sales \$800M-\$810M vs \$872.4M Est.

Financial news for MYGN dated on 2019-11-04: Myriad Genetics Sees Q2 Adj. EPS \$0.30-\$0.32 vs \$0.48 Estimate, Sales \$210M-\$212M vs \$221.4M Est.

Financial news for MYGN dated on 2019-11-04: Myriad Genetics Q1 Adj. EPS \$0.08 May Not Compare To \$0.32 Estimate, Sales \$186.3M Miss \$202.1M Estimate

Financial news for MYGN dated on 2019-11-03: The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight

Financial news for MYGN dated on 2019-10-24: The Daily Biotech Pulse: Acorda To Trim Jobs, GlaxoSmithKline Gets FDA Nod, Edward Lifesciences Posts Q3 Beat-And-Raise

Financial news for MYGN dated on 2019-10-23: Myriad Genetics Reports FDA Approval Of myChoice CDx Test

Financial news for MYGN dated on 2019-10-17: InVitae Shares Bounce Back Following Analyst Rebuttal To Short Seller Allegations

Financial news for MYGN dated on 2019-09-26: Benzinga's Top Upgrades, Downgrades For September 26, 2019

Financial news for MYGN dated on 2019-09-26: Bank of America Downgrades Myriad Genetics to Underperform

Financial news for MYGN dated on 2019-09-25: Myriad Genetics shares are trading lower despite no company-specific news. Stocks in the broader healthcare space have been volatile amid the 2020 Democratic primaries, in which healthcare policy has been a key issue.

Financial news for MYGN dated on 2019-09-25: 58 Biggest Movers From Yesterday

Financial news for MYGN dated on 2019-09-24: Myriad Genetics shares are trading higher. Unconfirmed reports say a Piper Jaffray analyst suggested Genomind, a competitor, resumed including specific drug recommendations in physician reports.

Financial news for MYGN dated on 2019-09-24: Myriad Genetics Shares Up 3.6% Over Last 30 Mins As Hearing Piper Jaffray Analyst Suggested A Co. Competitor, Genomind, Resumed Including Specific Drug Recommendations In Physician Reports

Financial news for MYGN dated on 2019-09-24: Bearish Blog Post Says Sees 45% Downside Risk In Myriad Genetics

Financial news for MYGN dated on 2019-09-16: Myriad Genetics Reports Research Collaboration With University Of Leeds, No Terms Disclosed

Financial news for MYGN dated on 2019-09-05: Myriad Genetics Highlights Publication Of Study Results Showing Effectiveness Of Prolaris Genetic Test In Men With Low-Risk Prostate Cancer

Financial news for MYGN dated on 2019-08-22: Hearing Piper Says Buy Myriad Genetic, Saying Medicare News Increase Target Market; Unconfirmed

Financial news for MYGN dated on 2019-08-19: 33 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for MYGN dated on 2019-08-17: Barron's Picks And Pans: American Eagle Outfitters, Chevron, Grocery Outlet And More

Financial news for MYGN dated on 2019-08-16: Shares of healthcare companies are

trading higher as US markets rebound from recent weakness following a yield curve inversion, which caused recession fears. Trump also recently announced the US would delay China tariffs, renewing hopes of a trade deal.

Financial news for MYGN dated on 2019-08-15: Myriad Genetics Option Alert: Sep 20 \$28 Calls at the Ask: 2500 @ \$0.651 vs 113 OI; Ref=\$22.87

Financial news for MYGN dated on 2019-08-15: 61 Biggest Movers From Yesterday

Financial news for MYGN dated on 2019-08-14: Mid-Afternoon Market Update: Dow Falls Over 700 Points; Myriad Genetics Shares Plummet

Financial news for MYGN dated on 2019-08-14: 48 Stocks Moving In Wednesday's Mid-Day Session

Financial news for MYGN dated on 2019-08-14: Mid-Day Market Update: Crude Oil Down Over 5%; Purple Innovation Shares Rises After Q2 Results

Financial news for MYGN dated on 2019-08-14: Mid-Morning Market Update: Markets Open Lower; Macy's Misses Q2 Estimates

Financial news for MYGN dated on 2019-08-14: Benzinga's Top Upgrades, Downgrades For August 14, 2019

Financial news for MYGN dated on 2019-08-14: What Caused The Opening Gap In Myriad Genetics?

Financial news for MYGN dated on 2019-08-14: 10 Biggest Price Target Changes For Wednesday

Financial news for MYGN dated on 2019-08-14: 32 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for MYGN dated on 2019-08-14: Deutsche Bank Maintains Hold on Myriad Genetics, Lowers Price Target to \$35

Financial news for MYGN dated on 2019-08-14: 31 Stocks Moving In Wednesday's Pre-Market Session

Financial news for MYGN dated on 2019-08-14: The Daily Biotech Pulse: Regeneron's Bad Cholesterol Drug Aces Late-Stage Trial, Oncolytics Offering

Financial news for MYGN dated on 2019-08-14: Myriad Genetics shares are trading lower after the company reported worse-than-expected Q4 EPS and sales results. The company also issued Q1 and FY20 guidance below analyst estimates.

Financial news for MYGN dated on 2019-08-14: Piper Jaffray Downgrades Myriad Genetics to Equal-Weight, Lowers Price Target to \$40

Financial news for MYGN dated on 2019-08-14: A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street

Financial news for MYGN dated on 2019-08-14: 8 Stocks To Watch For August 14, 2019

Financial news for MYGN dated on 2019-08-13: 10 Stocks Moving In Tuesday's After-Hours Session

Financial news for MYGN dated on 2019-08-13: Myriad Genetics shares are trading lower after the company reported worse-than-expected Q4 EPS and sales results. The company issued Q1 and FY20 EPS and sales guidance below analyst estimates.

Financial news for MYGN dated on 2019-08-13: Myriad Genetics Sees Q1 Adj. EPS \$0.30-\$0.32 vs \$0.42 Est., Sales \$200M-\$202M vs \$217.35M Est.; Sees FY20 Adj. EPS \$1.80-\$1.90 vs \$1.92 Est., Sales \$865M-\$875M vs \$921.99M Est.

Financial news for MYGN dated on 2019-08-13: Myriad Genetics Q4 Adj. EPS \$0.41 Misses \$0.47 Estimate, Sales \$215.4M Miss \$221.04M Estimate

Financial news for MYGN dated on 2019-08-13: Myriad Genetics Q4 Earnings Preview

Financial news for MYGN dated on 2019-08-13: The Daily Biotech Pulse: Jazz Goes Shopping, Portola Offering, Novellion Delays Quarterly Results

Financial news for MYGN dated on 2019-08-13: Earnings Scheduled For August 13, 2019

Financial news for MYGN dated on 2019-08-11: The Week Ahead In Biotech: Vanda Awaits FDA Decision, BioVie Plans IPO

Financial news for MYGN dated on 2019-08-07: Myriad Will Seek FDA Approval of

BRACAnalysis CDx(r) As a Companion Diagnostic for Lynparza(r) (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cancer

Financial news for MYGN dated on 2019-08-05: Deutsche Bank Maintains Hold on Myriad Genetics, Raises Price Target to \$45

Financial news for MYGN dated on 2019-08-02: Top 10 Most Overbought Stocks Via Benzinga Pro's Screener Tool For Fri., August 2, 2019

Financial news for MYGN dated on 2019-08-02: A Look At Benzinga Pro's Most-Searched Tickers For August 2, 2019

Financial news for MYGN dated on 2019-08-02: Myriad Genetics Shares Tick To Session High Following Unusual Option Activity: Aug. Monthly \$48 Calls At The Bid Showing Volume Of 500 Contracts vs Open Interest 5 Contracts

Financial news for MYGN dated on 2019-08-02: Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Friday., August 2, 2019

Financial news for MYGN dated on 2019-08-02: Benzinga's Top Upgrades, Downgrades For August 2, 2019

Financial news for MYGN dated on 2019-08-02: Bank of America Upgrades Myriad Genetics to Neutral

Financial news for MYGN dated on 2019-08-02: 100 Biggest Movers From Yesterday

Financial news for MYGN dated on 2019-08-01: Top 10 Most Overbought Stocks Via Benzinga Pro's Screener Tool For Thu., August 1, 2019

Financial news for MYGN dated on 2019-08-01: Mid-Afternoon Market Update: U.S. Stocks Turn Lower; Crude Oil Falls Over 8%

Financial news for MYGN dated on 2019-08-01: Myriad Genetics Shares Jump To 9-Month High On Insurance Coverage For Genetic Test

Financial news for MYGN dated on 2019-08-01: Mid-Day Market Update: Crude Oil Down Over 3%; SunPower Shares Spike Higher

Financial news for MYGN dated on 2019-08-01: 72 Stocks Moving In Thursday's Mid-Day Session

Financial news for MYGN dated on 2019-08-01: Mid-Morning Market Update: Markets Open Higher; General Motors Earnings Top Expectations

Financial news for MYGN dated on 2019-08-01: Myriad Genetics shares trading higher following news UnitedHealthcare issued a positive coverage decision for GeneSight.

Financial news for MYGN dated on 2019-08-01: Myriad Genetics 8-K Shows UnitedHealthcare Issued A Positive Coverage Decision For Pharmacogenetic Testing For Mutli-Gene Panels Including Co.'s GeneSight Psychotropic Test

Financial news for MYGN dated on 2019-07-29: 42 Stocks Moving In Monday's Mid-Day Session

Financial news for MYGN dated on 2019-07-29: Benzinga's Top Upgrades, Downgrades For July 29, 2019

Financial news for MYGN dated on 2019-07-29: Myriad Genetics shares are trading lower after Needham downgraded the company from Strong Buy to Hold.

Financial news for MYGN dated on 2019-07-29: Needham Downgrades Myriad Genetics to Hold

Financial news for MYGN dated on 2019-07-19: Myriad Genetics shares are trading higher after the company resolved a complaint tied to Medicare billing for the Company's hereditary cancer testing for \$9.1 million.

Financial news for MYGN dated on 2019-07-19: Myriad Genetics Says Has Resolved Complaint Filed By Qui Tam Realtor In 2017

Financial news for MYGN dated on 2019-07-10: Nearly 500 Kroger Pharmacies To Participate In GeneSight Program To Pilot Myriad Genetics' GeneSight Test

Financial news for MYGN dated on 2019-07-09: Benzinga's Top Upgrades, Downgrades For July 9, 2019

Financial news for MYGN dated on 2019-07-09: Cowen & Co. Downgrades Myriad Genetics to Market Perform

Financial news for MYGN dated on 2019-06-27: Myriad Genetics Highlights Publication Of Results From Study Showing Prolaris Test Can Accurately Predict 10-Year Risk Of Metastases In Men Newly Diagnosed With Localized Prostate Cancer

Financial news for MYGN dated on 2019-06-27: 54 Biggest Movers From Yesterday

Financial news for MYGN dated on 2019-06-26: Myriad Genetics Option Alert: Jul 19 \$26 Calls Sweep (2) near the Ask: 500 @ \$1.25 vs 1890 OI; Earnings 8/20 After Close [est] Ref=\$24.625

Financial news for MYGN dated on 2019-06-26: The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi, Vermillion Offering, PDL BioPharma CFO to Depart

Financial news for MYGN dated on 2019-06-25: The Daily Biotech Pulse: Genfit NASH Drug In China, Conatus Explores Sale, Gilead Stitches Up Immuno-Oncology Partnership

Financial news for MYGN dated on 2019-06-21: Pioneering genetic-testing company Myriad's biggest up-and-coming product could be at risk after scientists raised major

Financial news for MYGN dated on 2019-06-19: Myriad Genetics' Labs Unit Reports Japanese Ministry Of Health, Labour, Welfare Granted Second Manufacturing, Marketing Approval For BRACAnalysis Diagnostic System As Companion With Lynparza

Financial news for MYGN dated on 2019-06-12: Myriad Genetics Option Alert: Jul 19 \$26 Calls Sweep (23) near the Ask: 760 @ \$0.9 vs 851 OI; Ref=\$24.235

Financial news for MYGN dated on 2019-06-03: Myriad Genetics Announces New Results from Two Large Studies of Its myRisk Hereditary Cancer Test at American Society of Clinical Oncology

Financial news for MYGN dated on 2019-06-02: Myriad Genetics Announces BRACAnalysis CDx Companion Diagnostic Test Identifies Patients with Metastatic Pancreatic Cancer Who Benefited from Treatment with Lynparza at #ASCO19

Financial news for MYGN dated on 2019-05-29: The Daily Biotech Pulse: Inovio's Partner Scales Back R&D Collaboration, Genmab Seeks Nasdaq Listing, Bayer Gets Breakthrough Therapy Designation

Financial news for MYGN dated on 2019-05-24: The Daily Biotech Pulse: FDA Nod For Novocure, Dynavax Restructures, Therapix Receives Nasdaq Notice

Financial news for MYGN dated on 2019-05-23: The Daily Biotech Pulse: Breakthrough Therapy Designation For Iovance, Guardant Prices Offering, 2 Stocks to Debut

Financial news for MYGN dated on 2019-05-21: The Daily Biotech Pulse: Setback For Merck In Breast Cancer Study, Arrowhead to Join S&P SmallCap 600 Index, Ocular's Glaucoma Trial Fails

Financial news for MYGN dated on 2019-05-09: Myriad Genetics Highlights EndoPredict Test Identifies Women With Early-stage Breast Cancer Who Can Safely Forgo Extended Endocrine Therapy 5 Years After Diagnosis

Financial news for MYGN dated on 2019-05-09: Myriad Genetics Highlights Publication Of Data From Its EndoPredict Study In Clinical Cancer Research Journal

Financial news for MYGN dated on 2019-05-09: 95 Biggest Movers From Yesterday

Financial news for MYGN dated on 2019-05-08: 75 Stocks Moving In Wednesday's Mid-Day Session

Financial news for MYGN dated on 2019-05-08: Myriad Genetics shares are trading lower after the company reported worse-than-expected Q3 sales results; the company also provided Q4 and FY19 sales guidance below analyst estimates.

Financial news for MYGN dated on 2019-05-08: The Daily Biotech Pulse: Daiichi's Positive Breast Cancer Trial, Supernus Slumps, Axovant Reverse Split

Financial news for MYGN dated on 2019-05-07: Myriad Genetics Sees Q4 Adj. EPS \$0.48 vs \$0.48 Estimate, Sales \$220M vs \$225.3M Est.; FY19 Adj. EPS \$1.74 vs \$1.71 Est., Sales \$856M vs \$861.4M Est.

Financial news for MYGN dated on 2019-05-07: Myriad Genetics Q3 Adj. EPS \$0.46 Beats \$0.42 Estimate, Sales \$216.6M Miss \$217.46M Estimate

Financial news for MYGN dated on 2019-05-07: The Daily Biotech Pulse: Osmotica Flies, Catalyst Plummets, GW Pharma On Track To File For Expanded Use Of Epidiolex

Financial news for MYGN dated on 2019-05-03: Shares of companies in the diagnostics

and research space are trading higher in sympathy with Bruker, which reported better-than-expected Q1 EPS and sales results.

Financial news for MYGN dated on 2019-04-23: Myriad to Present Multiple Women's Health Studies At 2019 American College Of Obstetricians And Gynecologists Annual Meeting

Financial news for MYGN dated on 2019-04-10: 26 Stocks Moving In Wednesday's Pre-Market Session

Financial news for MYGN dated on 2019-04-09: Myriad Genetics Submits the First Module of the Premarket Approval Application to the FDA for its myChoice HRD CDx Test

Financial news for MYGN dated on 2019-04-04: Myriad Genetics, AstraZeneca, Merck Report Expansion Of Companion Diagnostic Partnership

Financial news for MYGN dated on 2019-03-14: Myriad Genetics shares are trading higher after the company reported the myPath Melanoma test received medicare coverage.

Financial news for MYGN dated on 2019-03-14: Myriad Genetics Reports myPath Test Received Medicare Coverage

Financial news for MYGN dated on 2019-03-11: Myriad Genetics Option Alert: May 17 \$32 Calls Sweep (3) near the Ask: 5000 @ \$1.75 vs 42 OI; Earnings 5/7 Before Open [est] Ref=\$29.1

Financial news for MYGN dated on 2019-03-06: Myriad Highlights Publication Of Expanded Carrier Screen Study In Genetics In Medicine

Financial news for MYGN dated on 2019-02-26: UPDATE: Myriad Genetics Says Will Seek FDA Approval Of BRACAnalysis CDx As Companion Diagnostic For Olaparib In Patient Population

Financial news for MYGN dated on 2019-02-26: Myriad Genetics Reports BRACAnalysis CDx Test Successfully Identified Patients With Metastatic Pancreatic Cancer Who Benefited From Treatment With Olaparib

Financial news for MYGN dated on 2019-02-11: Myriad Genetics Announces Its Prequel Prenatal Screen Has Expanded To Include All 23 Chromosome Pairs

Financial news for MYGN dated on 2019-02-06: Myriad Genetics shares are trading higher after the company reported Q2 sales of \$216.8M, beating the \$216.73M estimate. The company also issued Q3 EPS and sales guidance in the higher range of analyst estimates.

Financial news for MYGN dated on 2019-02-06: The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering

Financial news for MYGN dated on 2019-02-05: Myriad Genetics Sees Q3 Adj. EPS \$0.42-\$0.44 vs \$0.42 Est., Sales \$216M-\$218M vs \$215.9M Est., Sees FY19 Adj. EPS \$1.70-\$1.75 vs \$1.74 Est., Sales \$855M-\$865M vs \$863.69M Est.

Financial news for MYGN dated on 2019-02-05: Myriad Genetics Q2 EPS \$0.38 Misses \$0.41 Estimate, Sales \$216.8M Beat \$216.73M Estimate

Financial news for MYGN dated on 2019-02-05: Earnings Scheduled For February 5, 2019

Financial news for MYGN dated on 2019-01-16: CORRECTION: Recent Comments On Myriad Genetics Comes From SeekingAlpha Post From The Capitolist 'Myriad: FOIAs Reveal 50% Downside As Majority Of EBITDA Potentially At Risk From Reduced Reimbursement Rates'

Financial news for MYGN dated on 2019-01-16: Myriad Genetics Shares Fall ~1% Over Last Min.; Traders Attributing To Comments From The Capitolist SeekingAlpha Contributor 'Myriad: FOIAs Reveal 50% Downside As Majority Of EBITDA Potentially At Risk From Reduced Reimbursement Rates'

Financial news for MYGN dated on 2019-01-08: 24 Stocks Moving In Tuesday's Pre-Market Session

Financial news for MYGN dated on 2019-01-08: 65 Biggest Movers From Yesterday

Financial news for MYGN dated on 2019-01-07: Myriad Genetics shares are trading lower after a report, from the Southern Investigative Reporting Foundation, stated that Myriad Genetics has great difficulties telling the truth.

Financial news for MYGN dated on 2019-01-07: 'Myriad Genetics: This Company Has Great Difficulties Telling the Truth' -Report From Southern Investigative Reporting Foundation

Financial news for MYGN dated on 2019-01-04: Myriad Genetics Highlights GUIDED Study Published In 'Journal Of Psychiatric Research,' Showed 'individuals in the GeneSight cohort had 50% higher rate of remission, 30% higher rate of response, 11% great improvement in symptoms...'

Financial news for MYGN dated on 2019-01-04: Cowen & Co. Upgrades Myriad Genetics to Outperform

Financial news for MYGN dated on 2018-12-19: Myriad Genetics Announces FDA Approval Of BRACAnalysis CDxAs A Companion Diagnostic For AstraZeneca's Lynparza For Ovarian Cancer

Financial news for MYGN dated on 2018-12-19: Myriad Genetics Reports UK's National Institute For Health And Care Excellence Included Co.'s EndoPredict In Recommendations For Guiding Adjuvant Chemotherapy Decisions

Financial news for MYGN dated on 2018-12-10: 31 Stocks Moving In Monday's Pre-Market Session

Financial news for MYGN dated on 2018-12-07: Myriad Genetics Issues Release Highlighting Presentation Of New Data for Its EndoPredict(r) Breast Cancer Test At San Antonio Breast Cancer Symposium

Financial news for MYGN dated on 2018-11-30: Benzinga's Top Upgrades, Downgrades For November 30, 2018

Financial news for MYGN dated on 2018-11-30: Goldman Sachs Upgrades Myriad Genetics to Neutral, Raises Price Target to \$32

Financial news for MYGN dated on 2018-11-19: Myriad Announces \$50M Buyback

Financial news for MYGN dated on 2018-11-07: The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie

Financial news for MYGN dated on 2018-11-06: Myriad Genetics Reaffirms FY19 Adj. EPS Guidance \$1.70-\$1.75 vs \$1.72 Estimate, Sales Cut From \$880M-\$890M To \$855M-\$865M vs \$888M Est.

Financial news for MYGN dated on 2018-11-06: Myriad Genetics, Inc. Q1 EPS \$0.43 Beats \$0.30 Estimate, Sales \$202.3M Miss \$202.46M Estimate

Financial news for MYGN dated on 2018-11-06: The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering

Financial news for MYGN dated on 2018-11-06: Earnings Scheduled For November 6, 2018

Financial news for MYGN dated on 2018-11-04: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for MYGN dated on 2018-11-02: 76 Biggest Movers From Yesterday

Financial news for MYGN dated on 2018-11-01: 56 Stocks Moving In Thursday's Mid-Day Session

Financial news for MYGN dated on 2018-11-01: Hearing Morgan Stanley Out Defending Myriad Genetics; Firm Says Stock Move Today Reflects 'Confusion On The Regulatory Backdrop For Enetic Tests', Unconfirmed

Financial news for MYGN dated on 2018-10-23: Myriad Genetics Reports Clinical Study Using Foresight Carrier Screen Published In 'Genetics In Medicine'

Financial news for MYGN dated on 2018-10-22: Myriad Genetics Reports Its BRACAnalysis CDx Test Identified Patients With Newly-Diagnosed Advanced Ovarian Cancer Who May Benefit From Maintenance Treatment With Lynparza

Financial news for MYGN dated on 2018-10-16: Myriad Receives FDA Approval Of BRACAnalysis CDx As Companion Diagnostic For Pfizer's TALZENNA

Financial news for MYGN dated on 2018-10-10: 41 Stocks Moving In Wednesday's Mid-Day Session

Financial news for MYGN dated on 2018-10-10: Benzinga's Top Upgrades, Downgrades For October 10, 2018

Financial news for MYGN dated on 2018-10-10: 30 Stocks Moving In Wednesday's Pre-Market Session

Financial news for MYGN dated on 2018-10-10: Myriad Announces New Laboratory Agreement with Pfizer; Myriad Will Provide BRACAnalysis CDx Testing In Phase 2 Study Evaluating Pfizer's Talazoparib

Financial news for MYGN dated on 2018-10-10: PiperJaffray Upgrades Myriad Genetics to Overweight, Raises Price Target to \$53

Financial news for MYGN dated on 2018-09-26: UPDATE: Myriad Genetics Says GeneSight Study Showed 'use of CPGx yielded reduced spending for a commercial health plan across the patient population with psychiatric disorders, as well as among high-cost subpopulations'

Financial news for MYGN dated on 2018-09-26: Myriad Genetics Issues Press Release Highlighting Health Economic Study To Evaluate Financial Impact Of GeneSight CPGx Test On Major Commercial Health Plans In 'Personalized Medicine' Journal

Financial news for MYGN dated on 2018-09-06: 54 Biggest Movers From Yesterday

Financial news for MYGN dated on 2018-09-05: 40 Stocks Moving In Wednesday's Mid-Day Session

Financial news for MYGN dated on 2018-09-05: Stocks Which Set New 52-Week High Yesterday, September 4th

Financial news for MYGN dated on 2018-09-05: 10 Biggest Price Target Changes For Wednesday

Financial news for MYGN dated on 2018-09-05: Benzinga's Top Upgrades, Downgrades For September 5, 2018

Financial news for MYGN dated on 2018-09-05: The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results

Financial news for MYGN dated on 2018-09-05: Barclays Downgrades Myriad Genetics to Underweight, Lowers Price Target to \$30

Financial news for MYGN dated on 2018-09-04: Stocks Which Set New 52-Week High Friday, August 31

Financial news for MYGN dated on 2018-08-30: Stocks Which Set New 52-Week High Yesterday, August 29th

Financial news for MYGN dated on 2018-08-29: Stocks Which Set New 52-Week High Yesterday, August 28th

Financial news for MYGN dated on 2018-08-28: 10 Biggest Price Target Changes For Tuesday

Financial news for MYGN dated on 2018-08-28: Leerink Swann Maintains Market Perform on Myriad Genetics, Raises Price Target to \$49

Financial news for MYGN dated on 2018-08-24: Stocks Which Set New 52-Week High Yesterday, August 23rd

Financial news for MYGN dated on 2018-08-24: The Daily Biotech Pulse: Immunomedics' Bottom-Line Miss; Kala, Regeneron Await FDA Verdict

Financial news for MYGN dated on 2018-08-23: Stocks Which Set New 52-Week High Yesterday, August 22nd

Financial news for MYGN dated on 2018-08-23: The Daily Biotech Pulse: Novartis Breast Cancer Trial Meets Endpoint, Medpace's Offering, Dexcom Buys TypeZero

Financial news for MYGN dated on 2018-08-23: 50 Biggest Movers From Yesterday

Financial news for MYGN dated on 2018-08-22: 35 Stocks Moving In Wednesday's Mid-Day Session

Financial news for MYGN dated on 2018-08-22: Myriad Genetics shares are trading up 7.1% after the company late Tuesday reported a Q4 earnings beat and issued strong Q1 and 2019 sales guidance.

Financial news for MYGN dated on 2018-08-22: Barclays Maintains Equal-Weight on Myriad Genetics, Raises Price Target to \$38

Financial news for MYGN dated on 2018-08-22: The Daily Biotech Pulse: FDA Snub For Allergan, Myriad's Q4 Beat, Mallinckrodt's Stannsoporfin

Financial news for MYGN dated on 2018-08-22: 24 Stocks Moving In Wednesday's Pre-Market Session

Financial news for MYGN dated on 2018-08-21: Myriad Genetics shares are up 7.4% after hours following a Q4 earnings beat; The company also issued strong sales guidance for both Q1 and 2019.

Financial news for MYGN dated on 2018-08-21: Myriad Genetics Sees FY19 Adj. EPS \$1.70-\$1.75 vs \$1.40 Est., Sales \$880M-\$890M vs \$781.46M Est.

Financial news for MYGN dated on 2018-08-21: Myriad Genetics Sees Q1 Adj. EPS \$0.28-\$0.30 vs \$0.31 Est., Sales \$200M-\$202M vs \$191.64M Est.

Financial news for MYGN dated on 2018-08-21: Myriad Genetics Q4 Adj. EPS \$0.38 Beats \$0.33 Estimate, Sales \$200.9M Beat \$195.76M Estimate

Financial news for MYGN dated on 2018-08-21: The Daily Biotech Pulse: Merck's Keytruda Secures Approval For Expanded Label, ProPhase Labs Q2 Loss Narrows

Financial news for MYGN dated on 2018-08-21: Earnings Scheduled For August 21, 2018

Financial news for MYGN dated on 2018-08-19: The Week Ahead In Biotech: Conferences, PDUFA Dates And Earnings

Financial news for MYGN dated on 2018-08-14: Earnings Scheduled For August 14, 2018

Financial news for MYGN dated on 2018-08-13: Myriad Reschedules Release of Fiscal Fourth-Quarter 2018 Financial Results, Company Reaffirms Fiscal 2018 Guidance and Will Now Release Results on August 21, 2018

Financial news for MYGN dated on 2018-08-12: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

Financial news for MYGN dated on 2018-08-08: Stocks Which Set New 52-Week High Yesterday, August 7th

Financial news for MYGN dated on 2018-08-07: Stocks Which Set New 52-Week High Yesterday, August 6th

Financial news for MYGN dated on 2018-08-02: Stocks Which Set New 52-Week High Yesterday, August 1st

Financial news for MYGN dated on 2018-08-01: Myriad Genetics Filing Shows Registration For ~2.99M Share Common Stock Offering Via Selling Shareholders

Financial news for MYGN dated on 2018-07-26: Seeing Notable Block Trade In Myriad Genetics; 1M Shares at \$42.50

Financial news for MYGN dated on 2018-07-25: Stocks Which Set New 52-Week High Yesterday, July 24th:

Financial news for MYGN dated on 2018-07-12: Benzinga's Daily Biotech Pulse: AbbVie Files sNDA For Leukemia Drug, AcelRx Offering, Aurinia Starts Mid-Stage Trial

Financial news for MYGN dated on 2018-07-12: 44 Biggest Movers From Yesterday

Financial news for MYGN dated on 2018-07-11: Mid-Afternoon Market Update: Dow Down Over 200 Points; Achieve Life Sciences Shares Spike Higher

Financial news for MYGN dated on 2018-07-11: 4 Reasons Why Morgan Stanley Is Bullish On Myriad Genetics

Financial news for MYGN dated on 2018-07-11: Mid-Day Market Update: Crude Oil Down Over 2%; Simulations Plus Shares Plunge

Financial news for MYGN dated on 2018-07-11: 38 Stocks Moving In Wednesday's Mid-Day Session

Financial news for MYGN dated on 2018-07-11: Mid-Morning Market Update: Markets Open Lower; Fastenal Profit Tops Views

Financial news for MYGN dated on 2018-07-11: 8 Biggest Price Target Changes For Wednesday

Financial news for MYGN dated on 2018-07-11: Benzinga's Top Upgrades, Downgrades For July 11, 2018

Financial news for MYGN dated on 2018-07-11: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for MYGN dated on 2018-07-11: Morgan Stanley Upgrades Myriad Genetics to Overweight, Raises Price Target to \$55

Financial news for MYGN dated on 2018-06-21: Top-Five National Payer Issues Positive Coverage Decision For Myriad's Prolaris Test For Prostate Cancer

Financial news for MYGN dated on 2018-06-18: Myriad's BRACAnalysis CDx Supplementary PMA Accepted by FDA for Review as a Companion Diagnostic for Talazoparib in Metastatic Breast Cancer

Financial news for MYGN dated on 2018-06-04: 28 Stocks Moving In Monday's Pre-Market Session

Financial news for MYGN dated on 2018-06-01: Myriad Genetics Shares Up 6.0% After Co. Reported It Would Announce Results From Second Major Clinical Validation Study Of riskScore Test At ASCO '18

Financial news for MYGN dated on 2018-06-01: Myriad Genetics Highlights Will Offer Results From Second Major Clinical Validation Study Of riskScore Test At ASCO '18

Financial news for MYGN dated on 2018-05-31: UPDATE: Myriad Genetics Reports IMPACT Study Showed When Clinicians Used GeneSight Test Results To Guide Medication Selection, Patients Saw 28% Mean Reduction In Symptoms

Financial news for MYGN dated on 2018-05-31: Myriad Genetics Reports Results From IMPACT Study Of GeneSight By Wholly-Owned Subsidiary Assurex Health Will Be Highlighted At ASCP Annual Meeting

Financial news for MYGN dated on 2018-05-29: A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street

Financial news for MYGN dated on 2018-05-29: Myriad Genetics Signs Definitive Agreement to Acquire Counsyl for \$375M in Cash, Stock

Financial news for MYGN dated on 2018-05-23: Myriad Genetics Announces 7 New Payer Coverage Decisions for Prolaris

Financial news for MYGN dated on 2018-05-09: 53 Biggest Movers From Yesterday

Financial news for MYGN dated on 2018-05-08: Myriad Genetics Spikes On Better-Than-Expected Q3 Print

Financial news for MYGN dated on 2018-05-08: Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure

Financial news for MYGN dated on 2018-05-08: Myriad Genetics Raises FY18 Adj. EPS Guidance From \$1.11-\$1.16 to \$1.19-\$1.21 vs \$1.15 Est.

Financial news for MYGN dated on 2018-05-08: Myriad Genetics Q3 EPS \$0.31 Beats \$0.27 Estimate, Sales \$193.5M Beat \$188.22M Estimate

Financial news for MYGN dated on 2018-04-02: Benzinga Pro's 5 Stocks To Watch Today

Financial news for MYGN dated on 2018-04-02: Myriad Receives Pre-Market Approval for its BRACAnalysis Diagnostic System in Japan

Financial news for MYGN dated on 2018-03-21: Benzinga's Top Upgrades, Downgrades For March 21, 2018

Financial news for MYGN dated on 2018-03-21: The Market In 5 Minutes: China, Facebook, Nordstrom And More

Financial news for MYGN dated on 2018-03-21: Morgan Stanley Upgrades Myriad Genetics to Equal-Weight

Financial news for MYGN dated on 2018-03-14: 45 Biggest Movers From Yesterday

Financial news for MYGN dated on 2018-03-13: 35 Stocks Moving In Tuesday's Mid-Day Session

Financial news for MYGN dated on 2018-03-06: STAT News Publishes 'FDA approves first direct-to-consumer test for breast cancer risk'

Financial news for MYGN dated on 2018-02-15: Myriad Genetics PR Highlights JAMA Oncology Publication That Shows EndoPredict (EPclin) Significantly Outperforms Oncotype DX Recurrence Score in Early-Stage Breast Cancer

Financial news for MYGN dated on 2018-02-06: Myriad Genetics Reports Q2 Adj. EPS

\$0.31 vs \$0.24 Est., Sales \$194M vs \$188.8M Est.

Financial news for MYGN dated on 2018-02-06: A Preview Of Myriad Genetics' Q2 Earnings

Financial news for MYGN dated on 2018-02-02: Jim Cramer Advises His Viewers On Align Technology, Kennametal And More

Financial news for MYGN dated on 2018-01-29: Goldman Sachs Models 22% Downside To Myriad Genetics

Financial news for MYGN dated on 2018-01-29: Goldman Sachs Initiates Coverage On Myriad Genetics with Sell Rating, Announces \$32.00 Price Target

Financial news for MYGN dated on 2018-01-29: 28 Stocks Moving In Monday's Pre-Market Session

Financial news for MYGN dated on 2018-01-12: Myriad Receives FDA Approval of BRACAnalysis CDx as Companion Diagnostic for Lynparza in Patients with Metastatic Breast Cancer GLN

Financial news for MYGN dated on 2018-01-05: Benzinga's Top Upgrades, Downgrades For January 5, 2018

Financial news for MYGN dated on 2018-01-05: BTIG Research Initiates Coverage On Myriad Genetics with Buy Rating, Announces \$41.00 Price Target

Financial news for MYGN dated on 2018-01-03: Myriad Genetics Announces AstraZeneca to Use the Company's myChoice HRD Plus in an Exploratory Cancer Analysis

Financial news for MYGN dated on 2018-01-02: Stephens' Analysts Present Their Best Ideas For 2018

Financial news for MYGN dated on 2017-12-12: Myriad Genetics Reports BRACAnalysis CDx Test Effectively Identified Metastatic Breast Cancer Patients With Improved Outcomes From Pfizer's Talazoparib

Financial news for MYGN dated on 2017-11-15: Myriad Genetics' Latest Alliance To Boost GeneSight Reach

Financial news for MYGN dated on 2017-11-07: Myriad Genetics Sees FY18 Adj. EPS \$1-\$1.05, Sales \$750M-\$770M

Financial news for MYGN dated on 2017-11-07: Myriad Genetics Sees Q2 Adj. EPS \$0.22-\$0.24, Sales \$187M-\$189M

Financial news for MYGN dated on 2017-11-07: Myriad Genetics Reports Q1 Adj. EPS \$0.26 vs. \$0.21 Est., Sales \$190.2M vs. \$183.38M Est.

Financial news for MYGN dated on 2017-11-06: Myriad Genetics Reports Collaboration With CareFirst BlueCross BlueShield On Coverage With Evidence Development Study For Vectra DA Test

Financial news for MYGN dated on 2017-11-02: UPDATE: Myriad Says Patients Receiving GeneSight Test Achieved Clinically Meaningful and Statistically Significant Improvement in Remission Rates and Response Rates at Weeks vs Treatment-as-usual Group.

Financial news for MYGN dated on 2017-11-02: Myriad Announces GeneSight(r) Psychotropic Results from a Large Prospective Trial in Patients with Major Depressive Disorder

Financial news for MYGN dated on 2017-10-24: Myriad Submits BRACAnalysis CDx Application for Regulatory Approval in Japan for HER2- Metastatic Breast Cancer

Financial news for MYGN dated on 2017-10-19: GeneSight Announces 'Positive' for GeneSight in Patients with Generalized Anxiety Disorder

Financial news for MYGN dated on 2017-10-18: Myriad Genetics Reports BRACAnalysis CDx Supplementary PMA Accepted By FDA For Review As Companion Diagnostic For Lynparza In Metastatic Breast Cancer

Financial news for MYGN dated on 2017-10-02: Benzinga's Top Upgrades, Downgrades For October 2, 2017

Financial news for MYGN dated on 2017-10-02: Leerink Swann Initiates Coverage On Myriad Genetics with Market Perform Rating, Announces \$31.00 Price Target

Financial news for MYGN dated on 2017-09-15: Myriad Genetics Announces 'Positive'

Supporting New riskScore Test

Financial news for MYGN dated on 2017-09-05: Myriad Genetics Announces Launch Of riskScore Test

Financial news for MYGN dated on 2017-08-18: 15 Biggest Mid-Day Gainers For Friday

Financial news for MYGN dated on 2017-08-18: Increased Confidence Earns Myriad Genetics An Upgrade

Financial news for MYGN dated on 2017-08-18: Benzinga's Top Upgrades, Downgrades For August 18, 2017

Financial news for MYGN dated on 2017-08-18: A Peek Into The Markets: U.S. Stock Futures Edge Higher Ahead Of Consumer Sentiment Report

Financial news for MYGN dated on 2017-08-18: Deutsche Bank Upgrades Myriad Genetics to Hold

Financial news for MYGN dated on 2017-08-17: Myriad Genetics Announces Positive Coverage Decisions From Medicare And Anthem

Financial news for MYGN dated on 2017-08-08: Myriad Genetics Sees FY18 Adj. EPS \$1-\$1.05 vs \$1.08 Est., Sales \$750M-\$770M vs \$789.1M Est.

Financial news for MYGN dated on 2017-08-08: Myriad Genetics Sees Q1 Adj. EPS \$0.19-\$0.21 vs \$0.24 Est., Sales \$181M-\$183M vs \$191.9M Est.

Financial news for MYGN dated on 2017-08-08: Myriad Genetics Reports Q4 Adj. EPS \$0.30 vs \$0.26 Est., Sales \$200.5M vs \$193.7M Est.

Financial news for MYGN dated on 2017-08-01: Watch These 8 Huge Put Purchases In Tuesday Trade

Financial news for MYGN dated on 2017-07-31: Benzinga's Option Alert Recap From July 31

Financial news for MYGN dated on 2017-07-31: Myriad Genetics Option Alert: Aug 18 \$21 Puts at the Bid: 6846 @ \$0.201 vs 218 OI; Ref=\$24.27 Signals

Financial news for MYGN dated on 2017-06-29: JPMorgan Checks In On Myriad Genetics Following 30% Rally

Financial news for MYGN dated on 2017-06-21: 8-K From Myriad Genetics Shows Co. Agreed On New Long-Term Relationship With UnitedHealthcare Which Established Pricing For GeneSight, Polaris, Vectra DA, EndoPredict

Financial news for MYGN dated on 2017-06-06: Watch These 8 Huge Call Purchases In Tuesday Trade

Financial news for MYGN dated on 2017-06-05: Option Alert: Myriad Gen Jun 22.0 Calls: 2674 @ ASK \$0.20: 3504 traded vs 568 OI: Earnings 8/8 After Close (est) \$20.90 Ref

Financial news for MYGN dated on 2017-06-04: Myriad Announces BRACAnalysis CDx Test Identified Patients with Metastatic Breast Cancer Who Benefited from Treatment with Olaparib in Phase 3 OlympiAD Study

Financial news for MYGN dated on 2017-06-02: Myriad Genetics Issues Release Highlighting 17 Added Health Insurance Plans Now Covering EndoPredict

Financial news for MYGN dated on 2017-06-02: Myriad Genetics Gives update on myRisk Study

Financial news for MYGN dated on 2017-05-30: Option Alert: Myriad Gen Jun 21 Call; 5111 @Bid @\$0.20; Ref=\$20.18

Financial news for MYGN dated on 2017-05-12: Myriad Genetics Announced New Data Demonstrating Utility of Prolaris Test to Predict 10-Year Risk of Metastases in Men Treated for Prostate Cancer

Financial news for MYGN dated on 2017-05-08: Benzinga's Option Alert Recap From May 8

Financial news for MYGN dated on 2017-05-08: Option Alert: Myriad Genetics Jun. \$21 Puts: Volume of 2,500 at \$0.475/Contract

Financial news for MYGN dated on 2017-05-03: 20 Biggest Mid-Day Gainers For Wednesday

Financial news for MYGN dated on 2017-05-02: Myriad Genetics Reports Q3 Adj. EPS

\$0.27 vs \$0.23 Est., Sales \$196.9M vs \$189.1M Est.

Financial news for MYGN dated on 2017-04-27: Myriad Genetics and Clovis Oncology Sign Agreement for Use of FDA-Approved BRACAnalysis CDx Test to Identify Patients with Germline BRCA Mutations for Rubraca

Financial news for MYGN dated on 2017-04-06: Myriad Genetics, BeiGene Sign Agreement To Develop Diagnostics For Use With Beigene's BGB-290

Financial news for MYGN dated on 2017-04-05: Myriad Genetics Says Pivotal Results From 2 Studies On myPath Melanoma Test, Says Company Will Seek Reimbursement From Both Medicare and Private Payers

Financial news for MYGN dated on 2017-03-27: Tesaro Announces Expanded Development Program For Cancer Drug Niraparib, Stock Spikes Higher

Financial news for MYGN dated on 2017-03-27: Myriad Genetics Selling Off On TESARO Broad Label Details

Financial news for MYGN dated on 2017-03-27: Myriad Genetics Sells off to Low of \$18.75 on Volume

Financial news for MYGN dated on 2017-03-13: Myriad Genetics Launches the EndoPredict Test in the United States

Financial news for MYGN dated on 2017-03-06: 13G Filing Shows D.E. Shaw & Co Reporting 5% Stake In Myriad Genetics

Financial news for MYGN dated on 2017-02-23: MYRIAD GENETICS INC: HENDERSON JOHN T (Director) Buys 6,000 @ Avg Price: \$18.66 (Form4)

Financial news for MYGN dated on 2017-02-23: Myriad Genetics Pops to High on Volume

Financial news for MYGN dated on 2017-02-17: Myriad Genetics Reports Prolaris Test Significantly Improves the Risk Classification for One Third of Men Diagnosed with Localized Prostate Cancer

Financial news for MYGN dated on 2017-02-08: 20 Biggest Mid-Day Gainers For Wednesday

Financial news for MYGN dated on 2017-02-08: Benzinga's Top Upgrades, Downgrades For February 8, 2017

Financial news for MYGN dated on 2017-02-08: Myriad Genetics' Sell Thesis Is 'Largely Played Out'

Financial news for MYGN dated on 2017-02-08: The Market In 5 Minutes: Disney, Gilead Investors Not Too Pleased

Financial news for MYGN dated on 2017-02-08: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for MYGN dated on 2017-02-08: Ladenburg Thalmann Upgrades Myriad Genetics To Neutral

Financial news for MYGN dated on 2017-02-07: Myriad Genetics Sees Q3 Adj. EPS \$0.23-\$0.25 vs \$0.25 Est., Sales \$188M-\$190M vs \$190.2M Est.

Financial news for MYGN dated on 2017-02-07: UPDATE: Myriad Genetics Narrows FY17 Adj. EPS Outlook from \$1-\$1.10 to \$1-\$1.05 vs \$1.08 Est., Sales from \$740M-\$760M to \$745M-\$755M vs \$774.3M Est.

Financial news for MYGN dated on 2017-02-07: Myriad Genetics Narrows, Lowers Top End of FY17 Outlook

Financial news for MYGN dated on 2017-02-07: Myriad Genetics Reports Q2 Adj. EPS \$0.26 vs \$0.24 Est., Sales \$196.5M vs \$189.7M Est.

Financial news for MYGN dated on 2017-02-02: Watch These 8 Huge Put Purchases In Thursday Trade

Financial news for MYGN dated on 2017-02-01: Benzinga's Option Alert Recap From February 1

Financial news for MYGN dated on 2017-02-01: Option Alert: Myriad Genetics May 13.0 Puts Sweep: 582 @ ASK \$0.55: 582 traded vs 175 OI: Earnings 2/7 After Close \$16.14 Ref

Financial news for MYGN dated on 2017-01-18: Deutsche Bank Optimistic On Fundamentals In Life Science Tools/Diagnostics Sector

Financial news for MYGN dated on 2017-01-18: Deutsche Bank Initiates Coverage On Myriad Genetics At Sell, Announces \$15 Price Target

Financial news for MYGN dated on 2017-01-06: Myriad Genetics Gets Positive Test Coverage Decisions From Blue Cross Blue Shield Affiliate Plans for EndoPredict

Financial news for MYGN dated on 2016-12-27: Medicare Decisions For Myriad Present A Mixed Bag

Financial news for MYGN dated on 2016-12-23: Myriad Genetics Shares Down 4.71%; Hearing PiperJaffray Out Questioning Whether Medicare Will Continue Coverage Of Myriad's Vectra Blood Test

Financial news for MYGN dated on 2016-12-22: Myriad Genetics Announces Crescendo Bioscience Reports United Rheumatology Added Vectra DA to Clinical Practice Guidelines for Adults with RA

Financial news for MYGN dated on 2016-12-14: 10 Stocks With Highest Close In Three Weeks

Financial news for MYGN dated on 2016-11-12: Myriad Subsidiary Crescendo Bioscience Announces Four Studies with Vectra(r) DA Will Be Presented at the American College of Rheumatology 2016 Annual Meeting

Financial news for MYGN dated on 2016-11-07: Myriad Will Seek Japanese Regulatory Approval for BRACAnalysis CDx

Financial news for MYGN dated on 2016-11-02: 18 Biggest Mid-Day Losers For Wednesday

Financial news for MYGN dated on 2016-11-02: Worst Performing Industries For November 2, 2016

Financial news for MYGN dated on 2016-11-02: Stocks Hitting 52-Week Lows

Financial news for MYGN dated on 2016-11-02: Stephens & Co. Downgrades Myriad Genetics, Inc. - Common Stock to Equal-Weight

Financial news for MYGN dated on 2016-11-02: 10 Stocks That Rallied Four Days, Then Sold Off Yesterday

Financial news for MYGN dated on 2016-10-26: Exclusive: Myriad Genetics Discusses The Growing Market In Genetic Testing

Financial news for MYGN dated on 2016-10-21: Myriad Genetics Reports Formation of Relationship with ION Solutions to Deliver Quality Hereditary Cancer Tests and Services

Financial news for MYGN dated on 2016-10-13: Stocks Hitting 52-Week Lows

Financial news for MYGN dated on 2016-10-11: Bloomberg Reporter Caroline Chen Tweets: Federal judge on Oct. 7 refused \$TSRO request for restraining order on \$MYGN press release on NOVA -- via @business

Financial news for MYGN dated on 2016-10-10: What TESARO's Phase 3 NOVA Results Mean For Myriad Genetics

Financial news for MYGN dated on 2016-10-10: 8 Biggest Mid-Day Losers For Monday

Financial news for MYGN dated on 2016-10-10: Benzinga's Top Downgrades

Financial news for MYGN dated on 2016-10-10: Ladenburg Thalmann Downgrades Myriad Genetics, Inc. to Sell

Financial news for MYGN dated on 2016-10-10: 16 Stocks Moving In Monday's Pre-Market Session

Financial news for MYGN dated on 2016-10-09: Myriad Genetics Announces myChoice HRD Test Identifies Patients with Ovarian Cancer Who May Benefit from Treatment with Niraparib

Financial news for MYGN dated on 2016-10-07: Myriad Announces Four Poster Presentations at ESMO 2016

Financial news for MYGN dated on 2016-10-04: 9 Stocks Which Plummeted Three Days On Increasing Volume

Financial news for MYGN dated on 2016-09-22: Top Performing Industries For September 22, 2016

Financial news for MYGN dated on 2016-09-07: Myriad Genetics, Inc. Ticks Lower As, FDA Recommends Against Use Of Ovarian Cancer Screening Tests

Financial news for MYGN dated on 2016-09-07: Myriad Genetics Falls to Low of \$20.08 on Volume

Financial news for MYGN dated on 2016-08-19: CEO Capone Buys 10,000 Shares Of Myriad Genetics @\$21.24/Share -Form 4

Financial news for MYGN dated on 2016-08-10: Wednesday's Market Wrap: U.S. Stocks Trend Lower Mid-Week

Financial news for MYGN dated on 2016-08-10: Mid-Afternoon Market Update: Dow Falls 50 Points; Myriad Genetics Shares Decline Following Downbeat Results

Financial news for MYGN dated on 2016-08-10: 20 Biggest Mid-Day Losers For Wednesday

Financial news for MYGN dated on 2016-08-10: Mid-Day Market Update: Crude Oil Down 2%; Clean Energy Fuels Shares Climb Following Upbeat Earnings

Financial news for MYGN dated on 2016-08-10: Worst Performing Industries For August 10, 2016

Financial news for MYGN dated on 2016-08-10: Stocks Hitting 52-Week Lows

Financial news for MYGN dated on 2016-08-10: Even After Dipping Under \$21, Morgan Stanley Says Myriad Genetics Is Not Cheap

Financial news for MYGN dated on 2016-08-10: Mid-Morning Market Update: Markets Mostly Lower; Michael Kors Issues Downbeat Guidance

Financial news for MYGN dated on 2016-08-10: 10 Biggest Price Target Changes For Wednesday

Financial news for MYGN dated on 2016-08-10: Pre-Market Losers Aug. 10, 2016: MYGN Down 28.28%, KORS 3.91%, SPWR 28.69%, PRGO 11.58%, OA 10.62%, OHRP 9.56%

Financial news for MYGN dated on 2016-08-10: Barclays Downgrades Myriad, Says Hereditary Cancer Testing Losses Came Faster Than Expected

Financial news for MYGN dated on 2016-08-10: Benzinga's Top Downgrades

Financial news for MYGN dated on 2016-08-10: Gabelli & Co. Downgrades Myriad Genetics to Hold

Financial news for MYGN dated on 2016-08-10: 22 Stocks Moving In Wednesday's Pre-Market Session

Financial news for MYGN dated on 2016-08-10: Wells Fargo Downgrades Myriad Genetics to Market Perform

Financial news for MYGN dated on 2016-08-10: PiperJaffray Downgrades Myriad Genetics to Neutral

Financial news for MYGN dated on 2016-08-10: Barclays Downgrades Myriad Genetics to Equal-weight, Lowers PT to \$24.00

Financial news for MYGN dated on 2016-08-09: After-Hours Losers Aug. 9, 2016: SPWR Down 29%, MYGN 23%, TDW 18.5%, YUME 10.2%, ARWR 9.2%, LSCC 8.6%, LOAN 8.5%, CYBR 6%

Financial news for MYGN dated on 2016-08-09: Myriad Genetics Weak Guidance Drives Shares Down 20%

Financial news for MYGN dated on 2016-08-09: Myriad Genetics Shares to Resume Trade at 4:35 p.m. EDT

Financial news for MYGN dated on 2016-08-09: Myriad Genetics Sees FY17 Adj. EPS \$1-\$1.10 vs \$1.78 Est., Sales \$740M-\$760M vs \$790.6M Est.

Financial news for MYGN dated on 2016-08-09: Myriad Genetics Sees Q1 Adj. EPS \$0.25-\$0.27 vs \$0.43 Est., Sales \$168M-\$170M vs \$192M Est.

Financial news for MYGN dated on 2016-08-09: Myriad Genetics Reports Q4 Adj. EPS \$0.36 vs \$0.38 Est., Sales \$186.5M vs \$187.9M Est.

Financial news for MYGN dated on 2016-08-09: Myriad Genetics Shares Halted Ahead of Earnings

Financial news for MYGN dated on 2016-08-09: Earnings Scheduled For August 9, 2016

Financial news for MYGN dated on 2016-08-03: Myriad Genetics Signs Definitive Agreement to Acquire Assurex Health For \$225M Upfront And Potential \$185M Milestone Payments

Financial news for MYGN dated on 2016-07-29: Bank of America Downgrades Myriad Genetics to Underperform

Financial news for MYGN dated on 2016-07-11: Myriad Genetics Reports Results from EndoPredict Trial: 'Markedly Outperformed RS (Oncotype DX(r)) Across the 10-Year Follow-up Period" in a Large Head-to-Head Breast Cancer Study'

Financial news for MYGN dated on 2016-07-05: Barclays Explains Its Bullish Call On Myriad Genetics

Financial news for MYGN dated on 2016-06-29: Myriad Genetics Reports myChoice HRD Test Successfully Identified Patients Who Met Primary Endpoint in TESARO's Study with Niraparib

Financial news for MYGN dated on 2016-06-10: Myriad Genetics Subsidiary Crescendo Bioscience Announces New Data On Vectra TO Be Presented In London Today At 11:45am-1:30pm

Financial news for MYGN dated on 2016-06-07: Myriad Gets \$200 Million More For Share Repurchase Program

Financial news for MYGN dated on 2016-06-07: Myriad Reports Increase In Buyback Of \$200M

Financial news for MYGN dated on 2016-06-05: Myriad Genetics to Present Three New Hereditary Cancer Studies at the #ASCO16

Financial news for MYGN dated on 2016-05-31: Myriad Acquires Sividon Diagnostics For E\$35M Upfront and E\$15M In Additional Performance-Based Milestones

Financial news for MYGN dated on 2016-05-19: UPDATE: Myriad Genetics Says Believes Complaint Lacks Merit, Should Not Be Accepted

Financial news for MYGN dated on 2016-05-19: UPDATE: Myriad Genetics Says Has Complied with Requests, Provided Four Patients with Designated Record Set, All Requested Personal Health Info

Financial news for MYGN dated on 2016-05-19: Myriad Genetics Issues Statement on HIPAA Complaint from Four Patients

Financial news for MYGN dated on 2016-05-13: Top Performing Industries For May 13, 2016

Financial news for MYGN dated on 2016-05-04: Worst Performing Industries For May 4, 2016

Financial news for MYGN dated on 2016-05-03: Myriad Genetics Reports Q3 Adj. EPS \$0.41 vs \$0.38 Est., Sales \$190.5M vs \$184.9M Est.

Financial news for MYGN dated on 2016-04-25: Myriad Genetics Sells Off to Low of \$36.82 on Vol; Traders Attributing to Short Piece on Street Watchdog

Financial news for MYGN dated on 2016-04-19: Option Alert: MYGN Jun16 36.0 Puts Sweep: 832 @ ASK \$2.30: 832 traded vs 0 OI: Earnings 5/3 \$36.74 Ref

Financial news for MYGN dated on 2016-04-19: Myriad Genetics Sells Off to Low of \$37.96; Traders Attributing to Negative Leerink Comments

Financial news for MYGN dated on 2016-03-22: Downside in Shares of Myriad Genetics Over Last Few Mins May Be Related to Recent Tweet from Probes Reporter '\$MYGN Confirmed, Undisclosed SEC Investigation,' However This Report Was Published Yesterday

Financial news for MYGN dated on 2016-03-22: Myriad Genetics Downside Intensifies as \$37.40 Level Breached; Stock Down ~1.6% to \$37.08 for Session

Financial news for MYGN dated on 2016-03-22: Option Alert: MYGN May16 34.0 Puts Sweep: 2000 @ ASK \$1.25: 2000 traded vs 79 OI: Earnings 5/3 \$37.66 Ref

Financial news for MYGN dated on 2016-03-18: Myriad Says myRisk Hereditary Cancer Test Identifies 60% More Deleterious Mutations in Patients with Endometrial Cancer

Financial news for MYGN dated on 2016-03-15: Myriad Genetics Reports Presentation of

Second Pivotal Validation Study for myPath Melanoma Test

Financial news for MYGN dated on 2016-03-14: Myriad Genetics CEO To Speak Wednesday At 11AM edt On JP Morgan's Life Science & Diagnostics Conf. Call

Financial news for MYGN dated on 2016-03-08: Myriad Genetics Reports Advancement of Proprietary myVision Variant Classification Tools to Broader Range of Cancer Risk Genes

Financial news for MYGN dated on 2016-03-04: Friday's Early Global News: North Korea, Guns And Employment

Financial news for MYGN dated on 2016-02-22: Myriad Genetics Announces Expansion of Collaboration with Merck and Tesaro

Financial news for MYGN dated on 2016-02-03: Worst Performing Industries For February 3, 2016

Financial news for MYGN dated on 2016-02-02: Myriad Sees Q3 Rev. \$183-\$185M vs. Est. \$190M, EPS \$0.37-\$0.39 vs. Est. \$0.40; FY16 Rev. \$750-\$770M vs. Est. \$759.25M, EPS \$1.63-\$1.68 vs. Est. \$1.64

Financial news for MYGN dated on 2016-02-02: Myriad Genetics Reports Q2 EPS \$0.42 vs. Est. \$0.41, Rev. \$193.3M vs. Est. \$189.97M

Financial news for MYGN dated on 2016-01-07: Myriad Genetics, Thermo Fisher Two Top Life Science & Diagnostic Picks At Deutsche Bank

Financial news for MYGN dated on 2016-01-06: Avondale Partners Initiates Coverage on Myriad Genetics at Market Outperform, Announces \$50.00 PT

Financial news for MYGN dated on 2016-01-06: Deutsche Bank Initiates Coverage on Myriad Genetics at Buy, Calls Co Top Pick

Financial news for MYGN dated on 2016-01-06: Genomic Health Upgraded By Canaccord, \$44 Per Share Target Predicted

Financial news for MYGN dated on 2015-12-29: 10 Biotechs Short Sellers Are Betting Against

Financial news for MYGN dated on 2015-12-08: Goldman Upgrades Agilent Technologies, FEI Company And Myriad Genetics

Financial news for MYGN dated on 2015-12-08: Benzinga's Top Upgrades

Financial news for MYGN dated on 2015-12-08: Goldman Sachs Upgrades Myriad Genetics to Neutral, Raises PT to \$40.00

Financial news for MYGN dated on 2015-12-01: Myriad Genetics Subsidiary Crescendo Bioscience Says United States Patent and Trademark Office Grants Patent for Vectra DA, Patent Expected To Expire In 2031

Financial news for MYGN dated on 2015-11-16: Myriad RBM DiscoveryMAP Technology Identifies Novel Biomarkers That May Predict Increased Risk of Cardiovascular Events in Patients With Diabetes

Financial news for MYGN dated on 2015-11-07: Crescendo Bioscience Vectra DA Data to be Presented at American College of Rheumatology 2015 Annual Meeting

Financial news for MYGN dated on 2015-11-03: Myriad Sees Q2 EPS \$0.40-\$0.42 vs. Est. \$0.35, Rev. \$188-\$190M vs. Est. \$192.57M; FY16 EPS \$1.60-\$1.65 vs. Est. \$1.65, Rev. \$750-\$770M vs. Est. \$758.34M

Financial news for MYGN dated on 2015-11-03: Myriad Genetics Reports Q2 EPS \$0.41 Vs Est \$0.35, Sales \$183.5M vs Est \$177.89M

Financial news for MYGN dated on 2015-11-03: Earnings Scheduled For November 3, 2015

Financial news for MYGN dated on 2015-10-19: Top 4 NASDAQ Stocks In The Research Services Industry With The Highest EPS

Financial news for MYGN dated on 2015-10-09: Myriad to Show New Data on Its myRiskHereditary Cancer Test at the CGA-ICC Annual Meeting

Financial news for MYGN dated on 2015-10-07: US Stock Futures Signal Higher Start On Wall Street

Financial news for MYGN dated on 2015-10-07: Myriad Genetics, Tufts Health Plan Sign 3-Year Contract to Cover Prolaris for Members With Localized Prostate Cancer

Financial news for MYGN dated on 2015-10-07: Myriad Genetics and Tufts Health Plan Sign Agreement to Cover Prolaris(R) for Members With Localized Prostate Cancer

Financial news for MYGN dated on 2015-10-01: Myriad Names Jan Schluchter Chief Commercial Officer

Financial news for MYGN dated on 2015-09-24: Myriad Genetics Presents New Data on Its Companion Diagnostic and Prostate Cancer Tests at the European Society for Medical Oncology Annual Meeting

Financial news for MYGN dated on 2015-09-17: Top 4 NASDAQ Stocks In The Research Services Industry With The Highest Revenue

Financial news for MYGN dated on 2015-09-15: UBS Maintains Sell on Myriad Genetics, Reserves Caution on Co. Targets, Calls Stock a 'Show-Me' Story

Financial news for MYGN dated on 2015-09-09: Myriad Adds to Scientific Evidence for the myPlan(R) Lung Cancer Prognostic Test

Financial news for MYGN dated on 2015-09-01: Crescendo Bioscience, Subsidiary Of Myriad Genetics, Names Dr. Elena Hitraya Chief Medical Officer

Financial news for MYGN dated on 2015-08-25: Wells Fargo Upgrades Myriad Genetics to Outperform

Financial news for MYGN dated on 2015-08-13: Myriad Announces Favorable Medicare Final Coverage Decision for the Prolaris(R) Test

Financial news for MYGN dated on 2015-08-11: Tuesday's After-Hours Movers Led By Fossil, Cree And Myriad

Financial news for MYGN dated on 2015-08-11: Myriad Genetics Reports Q4 Adj. EPS \$0.41 vs. Est. \$0.42, Rev. \$189.9M vs. Est. \$187.77M

Financial news for MYGN dated on 2015-08-11: Must Watch Stocks for August 11, 2015

Financial news for MYGN dated on 2015-08-11: Earnings Scheduled For August 11, 2015

Financial news for MYGN dated on 2015-08-10: Fossil Group, Myriad Genetics Among The Earnings Reports To Keep An Eye On Tuesday

Financial news for MYGN dated on 2015-07-13: Short-Sellers Betting Against These Biotechs

Financial news for MYGN dated on 2015-07-13: 11 Stocks With Near-Term Catalysts

Financial news for MYGN dated on 2015-06-15: 10 Movers To Keep An Eye On This Monday

Financial news for MYGN dated on 2015-05-29: Myriad Significantly Improves the myChoice HRD Companion Diagnostic Test

Financial news for MYGN dated on 2015-05-27: 2 Small Cap Pharma Stocks Credit Suisse Loves

Financial news for MYGN dated on 2015-05-07: Myriad to Present New Clinical Data on Prolaris at AUA 2015 Annual Meeting

Financial news for MYGN dated on 2015-05-05: Myriad Genetics Earlier Said Expecting Q4 Adj. EPS \$0.40-\$0.42 vs \$0.49 Est., Sales \$187M-\$189M vs \$200M Est.; Cuts FY15 EPS Guidance from \$1.50-\$1.55 to \$1.44-\$1.46, Sales from \$730M-\$740M to \$720M-\$722M vs \$734M Est.

Financial news for MYGN dated on 2015-05-05: Myriad Genetics Q3 EPS \$0.40 vs \$0.40 est, Revenue \$180M vs \$182.4M est

Financial news for MYGN dated on 2015-05-05: Earnings Scheduled For May 5, 2015

Financial news for MYGN dated on 2015-04-29: 11 Buyout Targets Credit Suisse Is Watching

Financial news for MYGN dated on 2015-04-02: Top 4 Stocks In The Research Services Industry With The Highest Revenue

Financial news for MYGN dated on 2015-04-01: Myriad's Downside Case Might Not Matter

Financial news for MYGN dated on 2015-04-01: Myriad, AstraZeneca Expand Research Collaboration on Lynparza

Financial news for MYGN dated on 2015-03-26: Goldman Sachs Cuts Myriad Genetics To Sell, Ups Alere

Financial news for MYGN dated on 2015-03-26: Goldman Sachs Downgrades Myriad Genetics to Sell, Lowers PT to \$25.00

Financial news for MYGN dated on 2015-03-20: US Stock Futures Signal Higher Start On Wall Street

Financial news for MYGN dated on 2015-03-20: Myriad Announces Prolaris Test Biopsy Results from EMPATHY-P Study at European Association of Urology Annual Meeting

Financial news for MYGN dated on 2015-03-17: Myriad, BioMarin Expand Collaboration to Evaluate myChoice HRD as a Companion Diagnostic for Talazoparib

Financial news for MYGN dated on 2015-03-10: UBS Initiates Coverage on Myriad Genetics at Sell

Financial news for MYGN dated on 2015-03-04: Myriad Publishes myPath Melanoma Pivotal Validation Study in Journal of Cutaneous Pathology

Financial news for MYGN dated on 2015-02-25: Heavy News Day For Several Biotech Stocks

Financial news for MYGN dated on 2015-02-24: Myriad Approves \$200M Buyback Program

Financial news for MYGN dated on 2015-02-17: Top 5 Biotech Stocks That The Smart Money Doesn't Like

Financial news for MYGN dated on 2015-02-09: Quest Diagnostics, Myriad Genetics Dismiss BRCA Gene Patent Litigation

Financial news for MYGN dated on 2015-02-04: JMP Securities Upgrades Myriad Genetics, Says 'Revised Guidance Lowers The Bar'

Financial news for MYGN dated on 2015-02-04: Morning Market Losers

Financial news for MYGN dated on 2015-02-04: Wednesday Morning Movers: Gilead Sciences, Myriad Genetics Tumble Following Earnings

Financial news for MYGN dated on 2015-02-04: Benzinga's Top Upgrades

Financial news for MYGN dated on 2015-02-04: Benzinga's Top #PreMarket Losers

Financial news for MYGN dated on 2015-02-04: JMP Securities Upgrades Myriad Genetics To Outperform

Financial news for MYGN dated on 2015-02-04: JMP Securities Upgrades Myriad Genetics to Market Outperform, Announces \$50.00 PT

Financial news for MYGN dated on 2015-02-04: Mizuho Securities Downgrades Myriad Genetics to Neutral, Lowers PT to \$32.00

Financial news for MYGN dated on 2015-02-04: Credit Suisse Downgrades Myriad Genetics to Underperform, Lowers PT to \$30.00

Financial news for MYGN dated on 2015-02-03: Tuesday's After-Hours Movers: Gilead, Wynn Resorts And Chipotle Fall Following Earnings

Financial news for MYGN dated on 2015-02-03: Myriad Genetics Resumes Trading Down Over 19%

Financial news for MYGN dated on 2015-02-03: Myriad Announces Retirement of Peter Meldrum President, CEO

Financial news for MYGN dated on 2015-02-03: PREVIEW: Myriad Genetics to Resume Trading at 4:40 PM ET

Financial news for MYGN dated on 2015-02-03: Myriad Genetics Reports Q2 APS \$0.32 Vs Est \$0.35, Sales \$184.4M Vs Est \$183.41M

Financial news for MYGN dated on 2015-02-03: Myriad Genetics Shares Halted News Pending

Financial news for MYGN dated on 2015-02-03: Earnings Scheduled For February 3, 2015

Financial news for MYGN dated on 2015-01-23: Myriad, Pathway Genomics Settle BRCA Patent Infringement Case

Financial news for MYGN dated on 2015-01-12: Big Short Interest On These 5 Biotech Stocks

Financial news for MYGN dated on 2015-01-08: Myriad Obtains CE Mark for Tumor BRACAnalysis CDx; Launches Test in Europe as Companion Diagnostic for PARP Inhibitors

Financial news for MYGN dated on 2015-01-07: Barclays Initiates Coverage On Life Science Tools & Diagnostics, Names Thermo Fisher As 'Top Pick'

Financial news for MYGN dated on 2014-12-19: Myriad Receives FDA Approval of BRACAnalysis CDx

Financial news for MYGN dated on 2014-12-17: Shares of Myriad Genetics Fall ~2.5% Following Chatter of Lost Appeals Court Bid, Now Down ~1.6% for Session

Financial news for MYGN dated on 2014-12-17: Myriad Has Lost Appeals Court Bid to Block Breast Cancer Tests, Patents Found Invalid

Financial news for MYGN dated on 2014-12-17: Hearing Myriad Genetics Lost CAFC Hearing

Financial news for MYGN dated on 2014-12-12: A Closer Look At 5 Heavily Shorted Stocks

Financial news for MYGN dated on 2014-12-02: Study Shows Prolaris Could Save Healthcare System \$6B Over 10 Yrs.

Financial news for MYGN dated on 2014-11-20: TESARO and Myriad Genetics Form Collaboration Utilizing Myraid's myChoice HRD Companion Diagnostic

Financial news for MYGN dated on 2014-11-19: Myriad Genetics' Crescendo Bioscience Offers New Clinical Data on Vectra(R) DA at ACR

Financial news for MYGN dated on 2014-11-19: Crescendo Bioscience Highlights New Clinical Data on Vectra DA at ACR

Financial news for MYGN dated on 2014-11-12: Top Performing Industries For November 12, 2014

Financial news for MYGN dated on 2014-11-10: UPDATE: Morgan Stanley Initiates Coverage On Myriad Genetics As Survey Points To Greater Share Loss

Financial news for MYGN dated on 2014-11-10: Benzinga's Top Initiations

Financial news for MYGN dated on 2014-11-10: Morgan Stanley Initiates Myriad Genetics With Underperform

Financial news for MYGN dated on 2014-11-10: Crescendo Bioscience To Feature New Data On Vectra DA At 2014 ACR Meeting

Financial news for MYGN dated on 2014-11-10: Morgan Stanley Initiates Coverage on Myriad Genetics, Inc. at Underperform, Announces \$25.00 PT

Financial news for MYGN dated on 2014-11-04: Myriad Genetics, Inc. Sees Q2 EPS \$0.33-0.36; Sees Sales \$180.0M-185.0M

Financial news for MYGN dated on 2014-11-04: Myriad Genetics, Inc. Sees FY2015 EPS \$1.90-2.00; Sees Sales \$800.0M-820.0M

Financial news for MYGN dated on 2014-11-04: Myriad Genetics, Inc. Reports Q1 EPS of \$0.25 vs \$0.32 Est; Revenue of \$168.80M vs \$174.99M Est

Financial news for MYGN dated on 2014-11-04: Earnings Scheduled For November 4, 2014

Financial news for MYGN dated on 2014-11-03: Myriad and AbbVie Sign Expanded Agreement for Tumor BRACAnalysis CDx(TM)

Financial news for MYGN dated on 2014-10-24: Myriad Establishes Tumor BRACAnalysis CDx(TM) Laboratory in Europe

Financial news for MYGN dated on 2014-10-17: TGIF As Markets Rally; S&P 500 Posts Longest Weekly Loss Streak Since 2011

Financial news for MYGN dated on 2014-10-17: Morning Market Losers

Financial news for MYGN dated on 2014-10-17: Shares of Myriad Genetics to Resume Trade at 7:35 a.m. EDT

Financial news for MYGN dated on 2014-10-17: Myriad Reports Received Draft Medicare

Coverage for Polaris(R); Reports Prelim. Q1 Adj. EPS \$0.25 vs \$0.41 Est., Sales \$168M vs \$183.5M Est., Reaffirms FY15 Outlook

Financial news for MYGN dated on 2014-10-17: Myriad Genetics Shares Halted News Pending

Financial news for MYGN dated on 2014-10-09: Capital World Investors Reports 10.5% Passive Stake In Myriad Genetics as of September 30

Financial news for MYGN dated on 2014-10-08: Myriad Appoints R. Bryan Riggsbee As CFO

Financial news for MYGN dated on 2014-09-29: Myriad Reports Tumor Bracanalysis CDX Has Identified 44% More Candidates for PARP Therapy

Financial news for MYGN dated on 2014-09-22: Myriad Genetics Shares Spike to High

Financial news for MYGN dated on 2014-09-09: Myriad myPath Melanoma Test Reduced Indeterminate Cases By 76% And Changed Treatment In 35 % Of Cases

Financial news for MYGN dated on 2014-09-03: Myriad Publishes myRisk Hereditary Cancer Study In Cancer

Financial news for MYGN dated on 2014-08-14: Other Highlights from Tiger Global 13F: New Stake in Netflix, Liquidated Stake in Gap, Raised Stake in Charter, Lowered Stakes in Priceline, Myriad Genetics

Financial news for MYGN dated on 2014-08-13: FuelCell Upgrade; Amazon Announces New Product

Financial news for MYGN dated on 2014-08-13: SeaWorld Drops On Downbeat Results; Canadian Solar Shares Surge

Financial news for MYGN dated on 2014-08-13: Markets Rise; Macy's Lowers Comparable Sales Outlook

Financial news for MYGN dated on 2014-08-13: Morning Market Losers

Financial news for MYGN dated on 2014-08-12: Myriad Genetics, Inc. Sees FY2015 EPS \$1.90-2.00 Which May Not Compare \$2.39 Est; Sees Sales \$800.0M-820.0M Which May Not Compare \$776.60M Est

Financial news for MYGN dated on 2014-08-12: Myriad Genetics, Inc. Reports Q4 EPS of \$0.48 vs \$0.46 Est; Revenue of \$188.80M vs \$187.68M Est

Financial news for MYGN dated on 2014-08-12: Earnings Scheduled For August 12, 2014

Financial news for MYGN dated on 2014-08-01: Top 4 Stocks In The Research Services Industry With The Highest Profit Margin

Financial news for MYGN dated on 2014-07-18: Top 4 NASDAQ Stocks In The Research Services Industry With The Highest EPS

Financial news for MYGN dated on 2014-06-27: Myriad Genetics Shares Spike to High

Financial news for MYGN dated on 2014-06-09: Form 8-K from Myriad Genetics Shows CFO James Evans Will Retire

Financial news for MYGN dated on 2014-06-09: Mriad Announces James Evans CFO

Financial news for MYGN dated on 2014-06-02: Myriad Genetics Announces Partnership Aimed at Accelerating Hereditary Cancer Research

Financial news for MYGN dated on 2014-06-02: Myriad Presents Clinical Data on Myriad myRisk Hereditary Cancer Test at ASCO 2014

Financial news for MYGN dated on 2014-05-30: US Stock Futures Edge Lower Ahead Of Consumer Spending Report

Financial news for MYGN dated on 2014-05-30: Myriad Genetics Says Will Present Data on BRACAnalysis CDx(TM), HRD(TM) at 2014 ASCO Meeting

Financial news for MYGN dated on 2014-05-20: Myriad Says Test Predicts Mortality Risk For Prostate Cancer

Financial news for MYGN dated on 2014-05-15: 13F from Tiger Global Shows Raised Stakes in Charter, Myriad Genetics, Vipshops, Reduced Stakes in Mastercard, Motorola, New Stakes in Zillow, Trulia, Avis, Liquidated Stakes in Amazon, Netflix, Yahoo!, Groupon, TripAdvisor

Financial news for MYGN dated on 2014-05-14: Myriad Subsidiary Crescendo Bioscience's Vectra DA Predicts Radiographic Progression in Patients With Early RA

Financial news for MYGN dated on 2014-05-06: Myriad Genetics, Inc. Reports Q3 EPS of \$0.48 vs \$0.45 Est; Revenue of \$182.90M vs \$175.23M Est

Financial news for MYGN dated on 2014-05-06: Myriad Genetics and UnitedHealthcare Sign 3 Yr Deal To Make Cancer Tests Available To United Members

Financial news for MYGN dated on 2014-05-06: Earnings Scheduled For May 6, 2014

Financial news for MYGN dated on 2014-05-01: Myriad to Launch EndoPredict In Canada

Financial news for MYGN dated on 2014-04-23: Top 4 NASDAQ Stocks In The Research Services Industry With The Highest Revenue

Financial news for MYGN dated on 2014-04-14: Daniel B. Ravicher Tweet: 'Fed Cir Court of Appeals denies Myriad Genetics' \$MYGN motion to expedite appeal of denial of preliminary injunction against Ambry'

Financial news for MYGN dated on 2014-04-14: Bank of America Maintains Neutral on Myriad Genetics, Inc., Raises PO to \$42.00

Financial news for MYGN dated on 2014-04-07: UPDATE: Myriad Genetics Submits Premarket Approval to FDA for BRACAnalysis(R)

Financial news for MYGN dated on 2014-04-07: Myriad Genetics Submits Premarket Approval to FDA for Bracanalysis

Financial news for MYGN dated on 2014-04-04: Mizuho Securities Upgrades Myriad Genetics, Inc. to Buy

Financial news for MYGN dated on 2014-04-02: Mid-Afternoon Market Update: MannKind Hangs Onto its Gains as Yelp Shares Drop

Financial news for MYGN dated on 2014-04-02: Mid-Day Market Update: Apollo Drops After Q2 Results; MannKind Shares Spike Higher

Financial news for MYGN dated on 2014-04-02: Mid-Morning Market Update: Markets Flat; Monsanto Earnings Beat Street View

Financial news for MYGN dated on 2014-04-02: Benzinga's Volume Movers

Financial news for MYGN dated on 2014-04-02: Morning Market Movers

Financial news for MYGN dated on 2014-03-31: J.P. Morgan Reinstates Underweight Rating on Myriad Over LT Outlook Concerns

Financial news for MYGN dated on 2014-03-31: JP Morgan Reinstates Underweight on Myriad Genetics, Inc., Announces \$25.00 PT

Financial news for MYGN dated on 2014-03-27: Top 4 Stocks In The Research Services Industry With The Lowest PEG Ratio

Financial news for MYGN dated on 2014-03-24: Myriad Announces HRD Companion Diagnostic Collaboration With Tesaro

Financial news for MYGN dated on 2014-03-20: Myriad Genetics Reports SGO Issued New Clinical Practice Statements Regarding Hereditary Cancer Testing

Financial news for MYGN dated on 2014-03-11: Market Wrap For March 11: Markets End Slightly In The Red As Ukraine Worries Persist And Continued Chinese Conerns

Financial news for MYGN dated on 2014-03-11: Mid-Afternoon Market Update: Fuel Cell Companies Reverse Sharply on Citron Research Report

Financial news for MYGN dated on 2014-03-11: Mid-Day Market Update: Men's Wearhouse To Acquire Jos. A. Bank For \$65/Share; Myriad Shares Slip

Financial news for MYGN dated on 2014-03-11: Mid Morning Losers for March 11th, 2014

Financial news for MYGN dated on 2014-03-11: Mid-Morning Market Update: Markets Edge Lower; American Eagle Issues Weak Profit Forecast

Financial news for MYGN dated on 2014-03-11: Morning Market Losers

Financial news for MYGN dated on 2014-03-11: Myriad Genetics Shares Fall 8% Premarket as Company Fails to Block Competitor Ambry Genetics

Financial news for MYGN dated on 2014-03-11: Benzinga's Top #PreMarket Losers

Financial news for MYGN dated on 2014-03-11: Myriad Genetics' Motion to Block Rival Denied by US Court

Financial news for MYGN dated on 2014-03-03: Myriad Genetics Issues Clinical Utility Study for Prolaris, Says Submitted Proceed 500 Data to CMS for Medicare, Expecting Coverage by the End of June

Financial news for MYGN dated on 2014-02-26: 10 Healthcare Stocks With Strong Growth For 2014: Investment Idea Of The Day

Financial news for MYGN dated on 2014-02-19: Investing Like Martin Zweig: Growth With A Conservative Streak

Financial news for MYGN dated on 2014-02-18: New Stocks Make Most Attractive/Dangerous Lists For February

Financial news for MYGN dated on 2014-02-18: Myriad Genetics Publishes Positive Prolaris Data in the Journal of Urology

Financial news for MYGN dated on 2014-02-07: Market Wrap For February 7: Jobs Report Not Great, But Not Too Bad

Financial news for MYGN dated on 2014-02-07: US Stock Futures Up; All Eyes On Jobs Report

Financial news for MYGN dated on 2014-02-07: Credit Suisse Upgrades Myriad Genetics, Inc. to Neutral

Financial news for MYGN dated on 2014-02-05: Mid-Afternoon Market Update: Sprint Rises on News it Has the Financing to Acquire T-Mobile

Financial news for MYGN dated on 2014-02-05: Mid-Day Market Update: CH Robinson Shares Drop On Downbeat Results; Tableau Spikes Higher

Financial news for MYGN dated on 2014-02-05: Mid-Morning Market Update: Markets Open Lower; Time Warner Earnings Beat Street View

Financial news for MYGN dated on 2014-02-05: Benzinga's Top #PreMarket Gainers

Financial news for MYGN dated on 2014-02-05: Safeguard Scientifics Expects to Realize Approximately \$40M In Aggregate Cash Proceeds from Acquisition of Partner Crescendo Bioscience by Myriad Genetics

Financial news for MYGN dated on 2014-02-05: Stocks To Watch For February 5, 2014

Financial news for MYGN dated on 2014-02-04: Benzinga's M&A Chatter for Tuesday February 4, 2014

Financial news for MYGN dated on 2014-02-04: Myriad Genetics Shares Resume Trade Up 14%

Financial news for MYGN dated on 2014-02-04: Myriad Genetics Shares to Resume Trade at 4:35PM EST

Financial news for MYGN dated on 2014-02-04: Myriad Genetics, Inc. Sees FY2014 Sales \$740.0M-750.0M vs \$705.60M Est

Financial news for MYGN dated on 2014-02-04: Myriad Genetics Raises FY 2014 Guidance

Financial news for MYGN dated on 2014-02-04: Myriad Genetics, Inc. Reports Q2 EPS of \$0.66 vs \$0.46 Est; Revenue of \$204.10M vs \$176.02M Est

Financial news for MYGN dated on 2014-02-04: Myriad Genetics to Buy Crescendo Bioscience for \$270M in Cash

Financial news for MYGN dated on 2014-02-04: Myriad Genetics Halted News Pending

Financial news for MYGN dated on 2014-02-04: Earnings Scheduled For February 4, 2014

Financial news for MYGN dated on 2013-12-31: Market Wrap For December 31: Markets End The Year On A Positive Note

Financial news for MYGN dated on 2013-12-31: Bank of America Lowers PO on Myriad Genetics Following BRACA Pricing Cut

Financial news for MYGN dated on 2013-12-31: Bank of America Maintains Neutral on Myriad Genetics, Inc., Lowers PO to \$25.00

Financial news for MYGN dated on 2013-12-30: Market Wrap For December 30: Markets Quiet Ahead of New Year's Eve

Financial news for MYGN dated on 2013-12-30: Mid-Afternoon Market Update: Markets Roughly Flat as Social Media Names Slowly Recover Morning Losses

Financial news for MYGN dated on 2013-12-30: Mid-Day Market Update: Crocs Surges After Blackstone Investment Announcement; Twitter Shares Slip

Financial news for MYGN dated on 2013-12-30: Stocks Hitting 52-Week Lows

Financial news for MYGN dated on 2013-12-30: Morning Market Losers

Financial news for MYGN dated on 2013-12-30: Benzinga's Top Downgrades

Financial news for MYGN dated on 2013-12-30: Mizuho Securities Downgrades Myriad Genetics, Inc. to Neutral, Maintains \$24.00 PT

Financial news for MYGN dated on 2013-12-30: Benzinga's Top #PreMarket Losers

Financial news for MYGN dated on 2013-12-30: Myriad Genetics Expresses Concerns over CMS Not Valuing BRCA 2 Gene in 81211 Code, CMS 81211 Payment Rate -8K

Financial news for MYGN dated on 2013-12-16: Stocks To Watch For December 16, 2013

Financial news for MYGN dated on 2013-12-14: Myriad's Presents Positive Clinical Data on HRD Test at SABCS 2013

Financial news for MYGN dated on 2013-12-09: Myriad Genetics Announces Collaboration With Janssen

Financial news for MYGN dated on 2013-12-04: Myriad Genetics to Present Prolaris Data

Financial news for MYGN dated on 2013-12-03: Mid-Day Market Update: Dow Down Over 100 Points; Apple Shares Gain

Financial news for MYGN dated on 2013-12-03: UPDATE: JMP Securities Downgrades Myriad Genetics as Survey Hints at More Rapid Share Losses Than Anticipated

Financial news for MYGN dated on 2013-12-03: JMP Securities Downgrades Myriad Genetics, Inc. to Market Perform, Removes \$36.00 PT

Financial news for MYGN dated on 2013-12-02: Hearing Positive Cowen Comments on Myriad Genetics

Financial news for MYGN dated on 2013-12-02: Invitae Files Patent Infringement Suit Against Myriad Genetics

Financial news for MYGN dated on 2013-11-26: Invitae Responds Being Names as Defendant in Myriad Genetics Lawsuit

Financial news for MYGN dated on 2013-11-20: Myriad Genetics Says Received Second HRD Pact with BioMarin

Financial news for MYGN dated on 2013-11-05: Myriad Genetics Will Buyback Up to \$300M

Financial news for MYGN dated on 2013-11-05: Myriad Genetics, Inc. Reports Q1 EPS of \$0.68 vs \$0.46 Est; Revenue of \$202.50M vs \$167.64M Est

Financial news for MYGN dated on 2013-10-28: US Stock Futures Up; Apple Earnings In Focus

Financial news for MYGN dated on 2013-10-28: Myriad myPlan Lung Cancer Test Met Primary Endpoint in Validation Study

Financial news for MYGN dated on 2013-10-24: Myriad Genetics Says myRisk Cancer Test Highly Accurate in Key Validation Study

Financial news for MYGN dated on 2013-10-23: Option Alert: Myriad Genetics November 27 Call; 2,250 Contracts Traded @\$1.05; Currently \$25.16

Financial news for MYGN dated on 2013-10-22: Jefferies Maintains Hold on Myriad Genetics, Inc., Lowers PT to \$24.00

Financial news for MYGN dated on 2013-10-21: Option Alert: Myriad Genetics November 30 Call; 2,000 Contracts Traded @\$0.45; Currently \$24.02

Financial news for MYGN dated on 2013-10-21: UPDATE: Credit Suisse Downgrades Myriad

Genetics on Unclear Growth Potential

Financial news for MYGN dated on 2013-10-21: Credit Suisse Downgrades Myriad Genetics, Inc. to Underperform, Lowers PT to \$20.00

Financial news for MYGN dated on 2013-10-18: Option Alert: Myriad Genetics November 27 Call; 2,019 Contracts Traded @\$1.15; Currently \$24.77

Financial news for MYGN dated on 2013-10-17: Option Alert: Myriad Genetics November 26 Call, 1,850 Contracts Traded @\$1.05; Currently \$24.75

Financial news for MYGN dated on 2013-10-14: Myriad Says myPath Melanoma Test Highly Effective in Verification Study

Financial news for MYGN dated on 2013-10-11: UPDATE: SunTrust Initiates Coverage on Myriad Genetics on Pricing Risk

Financial news for MYGN dated on 2013-10-10: SunTrust Robinson Humphrey Initiates Coverage on Myriad Genetics, Inc. at Reduce, Announces \$17.00 PT

Financial news for MYGN dated on 2013-10-07: Myriad Genetics Reports myRisk Cancer Test Improves Colon Cancer Testing by 60%

Financial news for MYGN dated on 2013-10-01: Market Wrap For Tuesday, October 1: Government Down, Markets Up

Financial news for MYGN dated on 2013-10-01: Mid-Afternoon Market Update: Markets Remain Up As Government Shutdown Continues

Financial news for MYGN dated on 2013-10-01: Mid-Day Market Update: US Stocks Extend Gains; Lexicon Shares Surge

Financial news for MYGN dated on 2013-10-01: Mid-Morning Market Update: Markets Rise; Walgreen Earnings Surge 86%

Financial news for MYGN dated on 2013-10-01: Morning Market Movers

Financial news for MYGN dated on 2013-10-01: Benzinga's Top Pre-Market Gainers

Financial news for MYGN dated on 2013-10-01: Ladenburg Thalmann Upgrades Myriad Genetics, Inc. to Buy

Financial news for MYGN dated on 2013-10-01: Myriad Genetics Reports in 8-K Filing that CPT Code Pricing Error Should Take a 'Week or Two' to Correct

Financial news for MYGN dated on 2013-09-30: Selloff in Myriad Genetics May be attributed to 2013 Gapfill Payment Amounts - Clinical Laboratory Fee Schedule (CLFS) Posted on CMS.gov

Financial news for MYGN dated on 2013-09-30: Myriad Genetics Spikes Lower

Financial news for MYGN dated on 2013-09-25: US Stock Futures Drop Ahead Of New Home Sales, Durable Goods Data

Financial news for MYGN dated on 2013-09-25: UPDATE: Myriad's myPlan Lung Cancer Test Meets Primary Endpoint in Trial

Financial news for MYGN dated on 2013-09-25: Myriad's myPlan Lung Cancer Test Meets Primary Endpoint in Trial

Financial news for MYGN dated on 2013-09-05: Shares of Myriad Genetics Move Lower as Co. Reports Launch of myRisk Hereditary Cancer Panel

Financial news for MYGN dated on 2013-09-04: Myriad Genetics, AstraZeneca Expand Collaboration on Olaparib Phase 3 Clinical Trials

Financial news for MYGN dated on 2013-08-29: The Top 10 Financial Tweets For Thursday, August 29

Financial news for MYGN dated on 2013-08-13: Myriad Genetics, Inc. Sees FY2014 EPS \$1.87-1.94 vs \$1.85 Est; Sees Sales \$690.0M-710.0M vs \$663.30M Est

Financial news for MYGN dated on 2013-08-13: Myriad Genetics, Inc. Reports Q4 EPS of \$0.53 vs \$0.44 Est; Revenue of \$174.10M vs \$159.87M Est

Financial news for MYGN dated on 2013-08-13: Earnings Scheduled For August 13, 2013

Financial news for MYGN dated on 2013-06-24: Myriad and TESARO Enter Into Companion Diagnostic Agreement

Financial news for MYGN dated on 2013-06-17: DaVita, Myriad RBM Announce Biomarker Research Collaboration

Financial news for MYGN dated on 2013-06-14: Mid-Afternoon Market Update: Walter Energy Plummets as Oil Posts a Strong Rally

Financial news for MYGN dated on 2013-06-14: Afternoon Market Losers

Financial news for MYGN dated on 2013-06-14: Mid-Day Market Update: Stocks Move Lower, Groupen Rises on Analyst Upgrade

Financial news for MYGN dated on 2013-06-14: 'Happy Birthday' the Subject of Newest Copyright Litigation

Financial news for MYGN dated on 2013-06-14: Hearing Piper Defending Myriad Genetics

Financial news for MYGN dated on 2013-06-14: Mid-Morning Market Update: Markets Slightly Higher, Smithfield Posts Lower Profit

Financial news for MYGN dated on 2013-06-14: UPDATE: Bank of America Downgrades Myriad Genetics as Competitive Concerns Emerge

Financial news for MYGN dated on 2013-06-14: Benzinga's Top Pre-Market Losers

Financial news for MYGN dated on 2013-06-14: Myriad Ruling Causes 15 Percent Swing Thursday - Here's Why

Financial news for MYGN dated on 2013-06-14: Benzinga's Top Downgrades

Financial news for MYGN dated on 2013-06-14: JMP Securities Upgrades Myriad Genetics, Inc. to Market Outperform, Announces \$48.00 PT

Financial news for MYGN dated on 2013-06-14: RBC Capital Downgrades Myriad Genetics, Inc. to Sector Perform, Maintains \$32.00 PT

Financial news for MYGN dated on 2013-06-14: Bank of America Downgrades Myriad Genetics, Inc. to Neutral, Lowers PO to \$35.00

Financial news for MYGN dated on 2013-06-13: Market Wrap for Thursday, June 13: Strong Economic Reports Trigger Stock Rally

Financial news for MYGN dated on 2013-06-13: DJ Reporting Quest Diagnostics to Offer BRCA1, BRCA2 Test Later This Year

Financial news for MYGN dated on 2013-06-13: UPDATE: Myriad Shares Have Swung from Up Nearly 8% to Down 4% Over Last Hour

Financial news for MYGN dated on 2013-06-13: Myriad Genetics Shares Selling Off

Financial news for MYGN dated on 2013-06-13: Leerink Swann Downgrades Myriad Genetics, Inc. to Market Perform

Financial news for MYGN dated on 2013-06-13: Hearing CFRA Negative on Myriad Supreme Court Decision

Financial news for MYGN dated on 2013-06-13: Mizuho's Lawson Boosts Target on Myriad Genetics Shares from \$38 to \$43, Maintains Buy

Financial news for MYGN dated on 2013-06-13: Afternoon Market Gainers

Financial news for MYGN dated on 2013-06-13: Supreme Court Upholds Myriad's cDNA Patent Claims

Financial news for MYGN dated on 2013-06-13: UPDATE: Myriad Shares Pulling Back Very Slightly, Now Up 5-7%

Financial news for MYGN dated on 2013-06-13: Myriad Shares Resume Now Up 8%

Financial news for MYGN dated on 2013-06-13: UPDATE: Myriad Genetics Shares Halted Up 4.4%

Financial news for MYGN dated on 2013-06-13: Myriad Genetics Shares Halted on Limit-Up, Limit-Down

Financial news for MYGN dated on 2013-06-13: Myriad Genetics Shares Now Spike Higher, Now Up 4+%

Financial news for MYGN dated on 2013-06-13: Supreme Court Ruling Said to be Partial

Victory for Myriad

Financial news for MYGN dated on 2013-06-13: Mondaq Reporting Gene Patents Limited by High Court in Mixed Ruling for Myriad

Financial news for MYGN dated on 2013-06-13: Myriad Genetics Spikes Lower

Financial news for MYGN dated on 2013-06-07: UPDATE: Cantor Fitzgerald Initiates Coverage on Myriad Genetics on Position in Molecular Diagnostic Franchises

Financial news for MYGN dated on 2013-06-06: Cantor Fitzgerald Initiates Coverage on Myriad Genetics, Inc. at Buy, Announces \$40.00 PT

Financial news for MYGN dated on 2013-05-31: UPDATE: Jefferies Assumes Coverage on Myriad Genetics, Downgrades to Hold Ahead of SCOTUS Decision

Financial news for MYGN dated on 2013-05-31: Jefferies Initiates Coverage on Myriad Genetics, Inc. at Hold, Announces \$31.00 PT

Financial news for MYGN dated on 2013-05-15: US Stock Futures Down Ahead Profit Taking

Financial news for MYGN dated on 2013-05-15: Stocks To Watch For May 15, 2013

Financial news for MYGN dated on 2013-05-09: Myriad Genetics Targeting Five-Year Low-Mid Double-Digit Sales Growth, Mid Double-Digit EPS Growth, Oper. Margins Mid-to-High 30%'s

Financial news for MYGN dated on 2013-05-08: Mizuho Securities Upgrades Myriad Genetics, Inc. to Buy, Raises PT to \$34.00

Financial news for MYGN dated on 2013-05-07: Myriad Genetics, Inc. Sees FY2013 EPS \$1.65-1.67 vs \$1.58 Est; Sees Sales \$595.0M-600.0M vs \$583.50M Est

Financial news for MYGN dated on 2013-05-07: Myriad Genetics, Inc. Reports Q3 EPS of \$0.46 vs \$0.40 Est; Revenue of \$156.50M vs \$148.25M Est

Financial news for MYGN dated on 2013-05-07: Myriad Genetics, Inc. Reports Q3 EPS of \$0.46 vs \$0.40 Est; Revenue of \$156.50M; Raises Outlook

Financial news for MYGN dated on 2013-04-15: US SUPreme Court Seeks Compromise in Myriad's Gene-Patent Case

Financial news for MYGN dated on 2013-04-15: Myriad Genetics Spikes Higher

Financial news for MYGN dated on 2013-03-26: Myriad Genetics, Pharmamar Announces First Commercial Partnership with New HRD Test

Financial news for MYGN dated on 2013-03-06: A Peek Into The Market Before The Trading Starts

Financial news for MYGN dated on 2013-03-06: Myriad Genetics Says BRCA Testing Receives Designation Under Affordable Care Act

Financial news for MYGN dated on 2013-03-04: UPDATE: Oppenheimer Lowers PT on Myriad Genetics on Weaker BRAC Analysis Pricing

Financial news for MYGN dated on 2013-03-04: UPDATE: Jefferies Reiterates Buy Rating, Lowers PT on Myriad Genetics on New Medicare Code Values

Financial news for MYGN dated on 2013-03-04: Oppenheimer Maintains Perform on Myriad Genetics, Inc., Lowers PT to \$29.00

Financial news for MYGN dated on 2013-03-04: Jefferies Maintains Buy on Myriad Genetics, Inc., Lowers PT to \$31.00

Financial news for MYGN dated on 2013-02-11: PetSmart and Other Secular Growth Picks (ACT, MYGN, PETM, HLF)

Financial news for MYGN dated on 2013-02-05: Myriad Genetics, Inc. Reports Q2 EPS of \$0.42 vs \$0.38 Est; Revenue of \$149.10M vs \$143.71M Est

Financial news for MYGN dated on 2013-02-05: Myriad Genetics Reports Q2 EPS \$0.42, Sales \$149.1M, Raises FY13 Sales Guidance from \$570-585M to \$575-585M; Announces \$200M Buyback Plan

Financial news for MYGN dated on 2013-02-05: Ladenburg Thalmann Downgraded Myriad Genetics, Inc. to Neutral

Financial news for MYGN dated on 2013-01-03: UPDATE: JP Morgan Downgrades Underweight on Myriad Genetics on Risk/Reward

Financial news for MYGN dated on 2013-01-03: JP Morgan Downgrades Myriad Genetics, Inc. to Underweight, Maintains \$26.00 PT

Financial news for MYGN dated on 2012-12-10: Myriad Genetics Announces Deal with Sanofi

Financial news for MYGN dated on 2012-12-03: UPDATE: Goldman Sachs Downgrades Myriad Genetics to Neutral, Lowers PT

Financial news for MYGN dated on 2012-12-03: From Earlier: Mizuho Securities Downgrades Myriad Genetics, Inc. to Neutral, Lowers PT to \$30.00

Financial news for MYGN dated on 2012-12-03: Goldman Sachs Downgrades Myriad Genetics, Inc. to Neutral, Lowers PT to \$26.00

Financial news for MYGN dated on 2012-12-03: Goldman Sachs Downgrades Myriad Genetics, Inc. to Neutral

Financial news for MYGN dated on 2012-11-30: Myriad Says US Supreme Court to Hear Isolated DNA Patent Case

Financial news for MYGN dated on 2012-11-30: Gene Patents Get New Review by US Supreme Court in Myriad Case - Bloomberg

Financial news for MYGN dated on 2012-11-30: Myriad Genetics Resumes Trading

Financial news for MYGN dated on 2012-11-30: Myriad Genetics Halted on Circuit Breaker

Financial news for MYGN dated on 2012-11-30: Myriad Genetics Spikes Lower

Financial news for MYGN dated on 2012-11-06: Jefferies & Company Maintains Myriad Genetics at Buy, Raises PT from \$31 to \$33

Financial news for MYGN dated on 2012-11-05: Myriad Genetics Raises FY13 EPS Guidance from \$1.44-1.48 to \$1.50-1.55 vs \$1.47 Est, Sales from \$550-565M to \$570-585M vs \$563.4M Est

Financial news for MYGN dated on 2012-11-05: Myriad Genetics Reports Q1 EPS \$0.36 vs \$0.32 Est; Revenues \$133.4M vs \$129.50M Est

Financial news for MYGN dated on 2012-10-24: UPDATE: Bank of America Upgrades Myriad Genetics to Buy on Diversification Strategy

Financial news for MYGN dated on 2012-10-24: Bank of America Upgrades Myriad Genetics from Neutral to Buy, Raises PO from \$30 to \$32

Financial news for MYGN dated on 2012-10-10: Myriad's HRD Score Detects Loss of DNA Repair Function in Ovarian Cancer

Financial news for MYGN dated on 2012-10-01: UPDATE: Piper Jaffray Upgrades Myriad Genetics to Overweight on Reimbursement Strategy Confidence

Financial news for MYGN dated on 2012-10-01: Piper Jaffray Upgrades Myriad Genetics from Neutral to Overweight, Raises PT from \$28 to \$35

Financial news for MYGN dated on 2012-09-25: UPDATE: Credit Suisse Initiates Myriad Genetics at Neutral on Overhangs

Financial news for MYGN dated on 2012-09-25: Credit Suisse Initiates Coverage on Myriad Genetics at Neutral, Announces PT of \$28

Financial news for MYGN dated on 2012-09-24: Myriad Says Utah Medicare Will Add Prostate Test to Next Draft Non-Covered Service LCD

Financial news for MYGN dated on 2012-08-23: Rosetta Genomics (NASDAQ: ROSG), a developer and provider of

Financial news for MYGN dated on 2012-08-16: Myriad Genetics Confirms Positive Ruling in Gene Patent Case

Financial news for MYGN dated on 2012-08-16: Hearing Incorrect Newswire Report on Myriad Patent Decision

Financial news for MYGN dated on 2012-08-16: Myriad Spikes Lower, Hearing Court Decision on Patents

Financial news for MYGN dated on 2012-08-14: Myriad Genetics Guides FY EPS \$1.44-1.48 vs \$1.48 Est; Guides FY EPS \$550-565M vs \$552.3M Est

Financial news for MYGN dated on 2012-08-14: Myriad Genetics Reports Q4 EPS \$0.34 vs \$0.34 Est; Revenues \$133M vs \$131.85M Est

Financial news for MYGN dated on 2012-07-26: Myriad Genetics and Pharma Mar Enter Into Companion Diagnostic Agreement

Financial news for MYGN dated on 2012-07-25: Top 4 Stocks In The Research Services Industry With The Highest Cash

Financial news for MYGN dated on 2012-07-24: Bio-Rad and Myriad RBM Partner to Commercialize Multiplex Biomarker Kits for Life Science Research

Financial news for MYGN dated on 2012-07-02: UPDATE: Goldman Sachs Upgrades Myriad Genetics to Buy on Expanded Portfolio, Domestic Bias

Financial news for MYGN dated on 2012-07-02: Goldman Sachs Upgrades Myriad Genetics from Neutral to Buy

Financial news for MYGN dated on 2012-06-04: Myriad's Lung Cancer Prognosis Test Shown to Significantly Predict Survival in Early Stage Lung Cancer Patients

Financial news for MYGN dated on 2012-05-11: UPDATE: Bank of America Initiates Coverage on Myriad Genetics

Financial news for MYGN dated on 2012-05-11: Bank of America Initiates Coverage on Myriad Genetics at Neutral, Announces PO of \$28

Financial news for MYGN dated on 2012-05-02: Jefferies & Company Maintains Myriad Genetics at Buy, Raises PT from \$28 to \$31

Financial news for MYGN dated on 2012-05-01: Myriad Genetics Reports Q3 EPS \$0.34 vs \$0.32 Est; Revenues \$129.8M vs \$119.34M Est

Financial news for MYGN dated on 2012-03-28: Myriad and Cephalon Enter Into Companion Diagnostic Agreement

Financial news for MYGN dated on 2012-03-26: Human-Gene Patent Rehearing Order by High Court in Myriad Case

Financial news for MYGN dated on 2012-03-26: US High Court Orders Appeals Panel To Take New Look At Myriad Gene Patents

Financial news for MYGN dated on 2012-03-21: Hearing Cowen Positive on Myriad Genetics

Financial news for MYGN dated on 2012-03-20: Notable Put Options Activity in Myriad Genetics

Financial news for MYGN dated on 2012-03-20: Positive Rumors Circulate About Myriad Genetics

Financial news for MYGN dated on 2012-03-20: Hearing RBC Positive on Myriad Genetics

Financial news for MYGN dated on 2012-03-20: US High Court Invalidates Prometheus Patents On Medical Diagnostic Tests

Financial news for MYGN dated on 2012-02-02: Myriad's Prolaris Test Shown to Significantly Predict Biochemical Recurrence Risk After Prostatectomy

Financial news for MYGN dated on 2012-02-01: UPDATE: Auriga Raises Target on Myriad Genetics to \$28

Financial news for MYGN dated on 2012-01-31: Myriad Genetics Guides FY2012 EPS \$1.24-1.28 vs \$1.20-1.25 Est; Revenues \$465-475M vs \$445-465M Prior

Financial news for MYGN dated on 2012-01-31: Myriad Genetics Reports Q2 EPS \$0.33 vs \$0.31 Est; Revenues \$122.80M vs \$115.29M Est

Financial news for MYGN dated on 2012-01-25: Will Roche's Takeover Bid Help People Predict Diseases?

Financial news for MYGN dated on 2012-01-18: End-of-Day Market Summary for January 18, 2012

Financial news for MYGN dated on 2012-01-18: Myriad Genetics Acquires Exclusive

Rights to RAD51C Gene

Financial news for MYGN dated on 2011-11-02: Auriga Maintains Buy Rating and \$24 PT on Myriad Genetics

Financial news for MYGN dated on 2011-11-01: Myriad Genetics Reports Q1 EPS \$0.29 vs \$0.28 Est; Revenues \$110.5M vs \$106.49M Est

Financial news for MYGN dated on 2011-11-01: Top 4 Stocks In The Research Services Industry With The Highest Operating Margin

Financial news for MYGN dated on 2011-09-23: Benzinga's Top Upgrades

Financial news for MYGN dated on 2011-09-23: Goldman Sachs Upgrades Myriad Genetics to Neutral

Financial news for MYGN dated on 2011-09-12: Benzinga's Top Upgrades

Financial news for MYGN dated on 2011-09-12: A Peek Into The Market Before The Trading Starts

Financial news for MYGN dated on 2011-09-08: Myriad Genetics Makes Strategic Debt Investment

Financial news for MYGN dated on 2011-08-15: Myriad Announces New \$200 Million Share Repurchase Program

Financial news for MYGN dated on 2011-08-10: UPDATE: Auriga Lowers PT on Myriad Genetics to \$21

Financial news for MYGN dated on 2011-08-10: UPDATE: Goldman Sachs Reiterates Sell on Myriad Genetics, Reduces PT to \$18

Financial news for MYGN dated on 2011-08-10: Goldman Sachs Lowers PT On Myriad Genetics To \$18

Financial news for MYGN dated on 2011-08-09: Myriad Genetics Reports Q4 EPS \$0.30 vs \$0.29 Est

Financial news for MYGN dated on 2011-07-29: Options Brief: Myriad Genetics

Financial news for MYGN dated on 2011-07-13: Puts Purchased on Myriad Genetics

Financial news for MYGN dated on 2011-07-07: Morgan Stanley Discontinuations 7/6 Continued

Financial news for MYGN dated on 2011-06-29: Wednesday's Put/Call Ratio Leaders

Financial news for MYGN dated on 2011-06-29: Options Brief: Myriad Genetics, Inc.

Financial news for MYGN dated on 2011-06-29: Top 4 Small-Cap Stocks In The Research Services Industry With The Highest Cash

Financial news for MYGN dated on 2011-06-15: Benzinga's Top Downgrades

Financial news for MYGN dated on 2011-06-15: Auriga Downgrades Myriad Genetics to Hold, Reduces PT to \$25

Financial news for MYGN dated on 2011-06-15: Auriga Downgrades Myriad Genetics To Hold, Lowers PT To \$25

Financial news for MYGN dated on 2011-06-09: OnDose Study Demonstrates Need for Improved Dosing Approach for Colorectal Cancer Patients

Financial news for MYGN dated on 2011-06-06: Myriad's PROLARIS Test Shown to Significantly Predict Prostate Cancer Outcome From Needle Biopsy Tissue

Financial news for MYGN dated on 2011-06-01: Jefferies Provides Color on Myriad Genetics, Buy

Financial news for MYGN dated on 2011-05-19: Morgan Stanley Reiterates Equal-Weight on Myriad Genetics

Financial news for MYGN dated on 2011-05-10: Myriad Genetics Licenses Novel Technology From Chronix Biomedical (MYGN)

Financial news for MYGN dated on 2011-05-04: Goldman Sachs Upgrades PT On Myriad Genetics To \$19, Maintains Sell (MYGN)

Financial news for MYGN dated on 2011-05-04: Goldman Sachs Has Sell Rating On Myriad Genetics (MYGN)

Financial news for MYGN dated on 2011-05-04: Morgan Stanley Comments On Myriad Genetics Strong 3Q

Financial news for MYGN dated on 2011-05-03: Myriad Genetics Reports EPS of \$0.31 vs. \$0.25 Estimate; Revenues \$102.4M vs. \$98.11M Estimate (MYGN)

Financial news for MYGN dated on 2011-05-02: CEOWORLD TOP 5 higher priced Biotechnology stocks picks- BIIB, CBST, MYGN, REGN and ITMN

Financial news for MYGN dated on 2011-04-27: Myriad Genetics Announces Agreement to Acquire Rules-Based Medicine, Pay \$80M (MYGN)

Financial news for MYGN dated on 2011-04-27: Myriad Genetics Announces Agreement to Acquire Rules-Based Medicine (MYGN)

Financial news for MYGN dated on 2011-04-13: J.P. Morgan Comments On Myriad Genetics Risk/Reward Balanced

Financial news for MYGN dated on 2011-04-07: Global Hunter Maintains Neutral on Myriad Genetics (MYGN)

Financial news for MYGN dated on 2011-04-06: Myriad Genetics and BioMarin Pharmaceutical Inc. Enter Into Agreement

Financial news for MYGN dated on 2011-04-06: Goldman Sachs Reports Myriad Genetics Oral Arguments Hold Few Surprises

Financial news for MYGN dated on 2011-03-08: Pullback in Commodities Takes Pressure Off 03-08-2011

Financial news for MYGN dated on 2011-02-28: Top 4 Stocks In The Research Services Industry With The Highest ROE (GPRO, MYGN, ACTG, FORR)

Financial news for MYGN dated on 2011-02-22: Morningstar's Top Takeover Targets in 2011 (Guest Post)

Financial news for MYGN dated on 2011-01-31: Puts Purchased on Myriad Genetics (MYGN)

Financial news for MYGN dated on 2011-01-28: Myriad: EPS In-line, Beats on Revs - Analyst Blog

Financial news for MYGN dated on 2011-01-28: Myriad: EPS In-line, Beats on Revs - Analyst Blog

Financial news for MYGN dated on 2011-01-28: Options Brief: Myriad Genetics (MYGN)

Financial news for MYGN dated on 2011-01-28: Piper Jaffray Raises PT On Myriad Genetics To \$20

Financial news for MYGN dated on 2011-01-25: Bulls Bet on Myriad Genetics (MYGN)

Financial news for MYGN dated on 2011-01-24: Calls Purchased on Myriad Genetics (MYGN)

Financial news for MYGN dated on 2011-01-21: Benzinga's Top Pre-Market NASDAQ Gainers (CYTX, GLUU, MYGN, HILL)

Financial news for MYGN dated on 2011-01-12: Myriad Genetics Attracting Heavy Volume After Upgrade (MYGN)

Financial news for MYGN dated on 2011-01-12: Calls Purchased as Myriad Genetics Pops (MYGN)

Financial news for MYGN dated on 2010-12-21: Myriad Launches Panexia - Analyst Blog

Financial news for MYGN dated on 2010-12-21: Myriad Launches Panexia - Analyst Blog

Financial news for MYGN dated on 2010-12-17: Myriad Genetics Spikes On Court Ruling -Bloomberg (MYGN)

Financial news for MYGN dated on 2010-12-09: Myriad Strengthens Portfolio - Analyst Blog

Financial news for MYGN dated on 2010-12-09: Myriad Strengthens Portfolio - Analyst Blog

Financial news for MYGN dated on 2010-12-06: ETFs For Biotech M&A Mania

Financial news for MYGN dated on 2010-11-30: Myriad Stays Neutral - Analyst Blog

Financial news for MYGN dated on 2010-11-30: Myriad Stays Neutral - Analyst Blog

Financial news for MYGN dated on 2010-11-04: Myriad Beats by a Penny - Analyst Blog

Financial news for MYGN dated on 2010-11-03: Myriad Genetics Climbs After Earnings (MYGN)

Financial news for MYGN dated on 2010-10-13: Myriad Genetics Rising On Unusual Volume (MYGN)

Financial news for MYGN dated on 2010-10-13: Benzinga's Volume Movers (SIGA, AIXG, JOBS, MYGN)

Financial news for MYGN dated on 2010-10-13: Benzinga's Top Upgrades (MYGN, ALU, SFD, AU)

Financial news for MYGN dated on 2010-10-13: RBC Capital Upgrades MYGN To Outperform

Financial news for MYGN dated on 2010-10-06: Triple Negative Breast Cancer Patients May Benefits From Myriads Increased Screening

Financial news for MYGN dated on 2010-10-06: Triple Negative Breast Cancer Patients May Benefits From Myriads Increased Screening

Financial news for MYGN dated on 2010-10-05: Potential for Myriad's Bracanalysis - Analyst Blog

Financial news for MYGN dated on 2010-08-31: Myriad Genetics Announces \$100 Million Stock Repurchase (MYGN)

Financial news for MYGN dated on 2010-08-11: MYGN Posts Decent FQ4 Despite Weaker Patient Office Visits

Financial news for MYGN dated on 2010-08-11: Afternoon Market Update (MYGN, LCC, UAU, ALK)

Financial news for MYGN dated on 2010-08-11: Myriad Genetics Beats Estimates - Analyst Blog

Financial news for MYGN dated on 2010-08-11: Myriad Genetics Exceed Estimates But Guidance Is Mixed

Financial news for MYGN dated on 2010-08-11: A Peek Into The Market Before The Trading Starts

Financial news for MYGN dated on 2010-08-11: Citi Lowers Target On Myriad Genetics (MYGN)

Financial news for MYGN dated on 2010-08-11: Benzinga's Top Downgrades (CRK, AOSL, MYGN, TSCO)

Financial news for MYGN dated on 2010-08-11: Global Hunter Downgrades MYGN To Neutral

Financial news for MYGN dated on 2010-08-10: Myriad Genetics Reports Earnings; Updates Guidance (MYGN)

Financial news for MYGN dated on 2010-07-14: Calls Purchased on Myriad Genetics (MYGN)

Financial news for MYGN dated on 2010-07-09: Myriad Genetics Falling On Heavy Volume After J.P. Morgan Downgrade (MYGN)

Financial news for MYGN dated on 2010-07-09: MYGN Slips On Downgrade In Rating

Financial news for MYGN dated on 2010-07-09: Benzinga's Top Downgrades (PT, BBY, CNI, MYGN)

Financial news for MYGN dated on 2010-06-28: Calls Purchased on Myriad Genetics (MYGN)

Financial news for MYGN dated on 2010-06-14: Calls Purchased on Myriad Genetics (MYGN)

Financial news for MYGN dated on 2010-06-07: Top 5 Small-Cap NASDAQ Stocks In The Healthcare Sector With The Highest Cash (ONXX, ISIS, MYGN, CBST, VPHM)

Financial news for MYGN dated on 2010-05-05: Myriad Genetics (MYGN) Downgraded To Neutral At Piper Jaffray

Financial news for MYGN dated on 2010-05-05: News Summary (MYGN, ALK, CTL, Q)

Financial news for MYGN dated on 2010-05-05: Benzinga's Top Pre-Market Losers (ITMN, MYGN, GRMN, AVNR, MPEL)

Financial news for MYGN dated on 2010-05-05: Piper Jaffray Downgrades MYGN To Neutral

Financial news for MYGN dated on 2010-05-05: Top 5 Mid-Cap Stocks In The Healthcare Sector On The NASDAQ With The Lowest PEG Ratio (UTHR, WCRX, MYGN, ENDP, TLCR)

Financial news for MYGN dated on 2010-05-04: Benzinga's After Hours Decliners (MYGN, ITMN, TRLG)

Financial news for MYGN dated on 2010-03-30: Myriad Genetics Falls

Financial news for MYGN dated on 2010-03-30: Benzinga's Top Pre-Market Losers (TNDM, GNVC, HPJ, MYGN)

Financial news for MYGN dated on 2010-03-30: U.S. Equity Market Preview (BJ, BBI, CEPH, DHR, MYGN)

Financial news for MYGN dated on 2010-03-29: Myriad Genetics Falling In After Hours (MYGN, CEPH)

Financial news for MYGN dated on 2010-03-21: How Will Obama-Care Play Into The Markets And ETFs?

Financial news for MYGN dated on 2010-02-03: Benzinga's Volume Movers (APKT, AUXL, NETL, MYGN, ACOR)

Financial news for MYGN dated on 2010-02-03: Pharma Stocks Dive On Missed Expectations

Financial news for MYGN dated on 2010-02-03: MYGN To Outperform In The Short Term On Strong December Quarter Results

Financial news for MYGN dated on 2010-02-02: Benzinga's After Hours Gainers (AOL, SU, NETL, MYGN)

Financial news for MYGN dated on 2010-02-02: 2010 Fund Performance Period 1

Financial news for MYGN dated on 2010-01-25: Stocks That Created New 52-Week Lows (CRIC, CCBP, GIGM, MYGN, RUTHR)

Financial news for MYGN dated on 2010-01-18: Bookkeeping: Weekly Changes to Fund Positions Year 3, Week 24

Financial news for MYGN dated on 2010-01-15: Reviewing Recent Sales

Financial news for MYGN dated on 2010-01-12: Bookkeeping: Closing Human Genome Sciences (HGSI)

Financial news for MYGN dated on 2010-01-12: Bookkeeping: Closing Myriad Genetics (MYGN) as Oppenheimer Analyst Brings Out the Hammer

Financial news for MYGN dated on 2010-01-07: Partnership Likely To Boost Myriad Genetics' (MYGN) Sales By An Additional 15%

Financial news for MYGN dated on 2009-12-28: Bookkeeping: Weekly Changes to Fund Positions Year 3, Week 21

Financial news for MYGN dated on 2009-12-23: Bookkeeping: Restarting Myriad Genetics (MYGN)

Financial news for MYGN dated on 2009-11-30: Likely Torch Bearers In The Market If The Economic Recovery Sustains, WSFS, PEI, IDTI, MCHP, MWA

Financial news for MYGN dated on 2009-11-11: Benzinga's Top Upgrades (PALM, TRST, MYGN, COLM, SFD, FLR)

Financial news for MYGN dated on 2009-11-05: Bookkeeping: Closing Myriad Genetics (MYGN) as Earnings Fail to Provide a Charge

Financial news for MYGN dated on 2009-11-04: Cramer Talks About MYGN, ERTS, VIA, NSC, BNI

Financial news for MYGN dated on 2009-10-20: Bookkeeping: Adding Back some Atheros Communciations (ATHR), Cutting Much of Myriad Genetics (MYGN)

Financial news for MYGN dated on 2009-10-05: Top 5 Stocks with Best ROE (FSLR, GGG, IDCC)

Financial news for MYGN dated on 2009-09-27: Limit Buy Order List

Financial news for MYGN dated on 2009-09-25: Bookkeeping: Restarting Position in Myriad Genetics (MYGN)

Financial news for MYGN dated on 2009-08-18: WallStSense.com Fundamental & Technical Coverage of MYGN, JRCC, QGEN, QLGC, MDRX and OVTI